

## Appendix A. Search Strategy

### MEDLINE 1966-August Week 4 2005

<u>#</u>	<u>Search History</u>	<u>Results</u>
1	exp Hypertension, Renal/	15140
2	exp Renal Artery Obstruction/	7388
3	renal arter\$ stenosis.tw.	3264
4	renal arter\$ dis\$.tw.	390
5	renovascular dis\$.tw.	613
6	reno vascular dis\$.tw.	6
7	renal vascular dis\$.tw.	156
8	(arvd or "atherosclerotic renovascular dis\$").tw.	302
9	renal steno\$.tw.	49
10	steno\$ kidney.tw.	137
11	renovascular steno\$.tw.	27
12	or/1-11	20249
13	limit 12 to humans	15628
14	limit 13 to english language	10148
15	limit 14 to (addresses or bibliography or biography or case reports or congresses or consensus development conference or consensus development conference, nih or dictionary or directory or editorial or festschrift or government publications or interview or lectures or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or "review of reported cases")	2736
16	14 not 15	7412
17	limit 16 to "all adult (19 plus years)"	4222
18	16 not 17	3190
19	limit 18 to "all child (0 to 18 years)"	488
20	16 not 19	6924
21	limit 20 to (guideline or practice guideline or "review" or review, academic or "review literature" or review, multicase or review, tutorial)	1316
22	limit 20 to meta analysis	8
23	20 not (21 or 22)	5601
24	follow-up studies/	303611
25	(follow-up or followup).tw.	332435
26	exp Case-Control Studies/	288665
27	(case adj20 control).tw.	43581
28	exp Longitudinal Studies/	498762
29	longitudinal.tw.	61304
30	exp Cohort Studies/	536922
31	cohort.tw.	70605
32	(random\$ or rct).tw.	315873
33	exp Randomized Controlled Trials/	38577

## Appendix A. Search Strategy (continued)

<b>#</b>	<b><u>Search History</u></b>	<b><u>Results</u></b>
34	exp random allocation/	53586
35	exp Double-Blind Method/	82631
36	exp Single-Blind Method/	9171
37	randomized controlled trial.pt.	204593
38	clinical trial.pt.	412355
39	controlled clinical trials/	2929
40	(clin\$ adj trial\$.tw.	88180
41	((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (blind\$ or mask\$)).tw.	79196
42	exp PLACEBOS/	23902
43	placebo\$.tw.	90025
44	exp Research Design/	194218
45	exp Evaluation Studies/	529271
46	exp Prospective Studies/	190597
47	exp Comparative Study/	1211784
48	or/24-47	2748065
49	23 and 48	2167

## Sample Data Extraction Form

Author (first)	Year	Identifier	Interventions	Modifier topics
		Medline UI:	Angioplasty vs Medical Angioplasty only Medical treatment only Natural history only	Pre-intervention predictors of outcome (Q2) Treatment variable predictors of outcome (Q3)
		Ref ID:		

<b>Study Design</b>		<b>Intervention Dates:</b>	<b>Follow-up dates</b>	
Randomized controlled trial Non-randomized comparative trial Prospective cohort (pre-post, single arm) Retrospective cohort			<b>Follow-up times</b>	
<b>Per patient analysis?</b>	<b>Both ?</b>	<b>Setting / Country:</b>	<b>Mean Follow-up</b>	
<b>Per Kidney analysis?</b>			<b>Funding:</b>	

Inclusion criteria	Exclusion criteria
<b>Definition of RAS:</b>	
<b>Other:</b>	
<b>Comments:</b>	

<b>Were eligibility criteria the same for all arms? (Describe differences)</b>
<b>Comments:</b>

Description of ANGIOPLASTY Intervention	Description of MEDICAL Intervention		
<b>Stent type:</b>	<b>BP Goal:</b>		
<b>Distal protection device:</b>	<b>Drug</b>	<b>Dose</b>	<b>Frequency</b>
<b>Other adjunct technique:</b>			
<b>Peri-procedural Rx:</b>			
<b>Other information:</b>			
<b>Comments:</b>			

Outcomes	Incl?	Definitions
Survival / Mortality		
Acute / Flash pulmonary edema		
Diastolic dysfunction		
Other CVD outcomes:		
Kidney function/structure:		

**Appendix B. Sample Data Extraction Form (continued)**

Blood pressure control:			
Adverse events			
<b>Comments:</b>			

<b>Cofactors / Predictors</b>	<b>Incl?</b>	<b>Definitions</b>	<b>Threshold</b>
Imaging test:			
Laboratory test:			
Clinical exam test:			
Demographics:			
Concurrent diseases:			
Anatomic characteristic:			
% Stenosis:			
Bilateral stenoses / solitary kidney stenosis			
Peri-procedural Rx:			
Type of stent:			
Distal protection device:			
ARAS etiology:			
Predominant clinical presentation:			
Blood pressure:			
Other:			
<b>Comments:</b>			

<b>Quality Assessment for RCTs</b>	
<b>Blinding:</b>	<b>Allocation concealment?</b>
<b>Intention-to-treat?</b>	<b>Other:</b>
<b>Comments:</b>	

<b>Quality Assessment for non-randomized and cohort studies:</b>
<b>Limitations:</b>
<b>Comments:</b>

<b>Characteristics of Enrolled Patients at Baseline</b>			
<b>Mean Age:</b>	<b>Age range:</b>	<b>Race:</b>	
<b>% Male:</b>			
<b>Mean BP</b>	<b>BP range:</b>	<b>Duration of HTN:</b>	
<b>% Stenosis:</b>	<b>Location of stenoses:</b>	<b>Test used to measure stenosis:</b>	
<b>% Bilateral stenosis:</b>			
<b>Mean GFR/CrCl/SCr:</b>	<b>units:</b>	<b>Range:</b>	<b>Other kidney:</b>
<b>CVD:</b>			

**Appendix B. Sample Data Extraction Form (continued)**

<b>Medical management at baseline:</b>
<b>Other:</b>
<b>Comments:</b>

<b>Sub-Groups Enrolled &amp; Analyzed</b>		
<b>N enrolled with RAS (total):</b>	<b>with ARAS:</b>	<b>ARAS analyzed separately (if mixed population)?</b>
<b>N analyzed with RAS (total):</b>	<b>with ARAS:</b>	
<b>N analyzed who had angioplasty (total):</b>	<b>plasty+stent:</b>	<b>Stent analyzed separately (if mixed interventions)?</b>
<b>Other mixtures of populations:</b>		
<b>Comments:</b>		

<b>Disposition of Patients (Arteries if nd on patients)</b>			
<b>ANGIOPLASTY</b>			
<b>N enrolled:</b>	<b>N had Plasty:</b>	<b>N successful Plasty</b>	
<b>Other details re: patients:</b>			
<b>N complete follow-up:</b>	<b>Dropout %:</b>	<b>Dropout reasons:</b>	
<b>Mean duration follow-up:</b>		<b>Duration range:</b>	
<b>MEDICAL TREATMENT</b>			
<b>N enrolled:</b>	<b>N received Rx:</b>		
<b>Other details re: patients:</b>			
<b>N complete follow-up:</b>	<b>Dropout %:</b>	<b>Dropout reasons:</b>	
<b>Mean duration follow-up:</b>		<b>Duration range:</b>	
<b>Comments:</b>			

**(Copy a Separate table for each outcome-duration combination)**

<b>Outcome:</b>	<b>ANGIOPLASTY</b>			<b>MEDICAL TREATMENT</b>		
	<b>N</b>	<b>Value (or n)</b>	<b>SE/SD</b>	<b>N</b>	<b>Value (or n)</b>	<b>SE/SD</b>
<b>Baseline value</b>						
<b>Final value</b>						
<b>Difference</b>						
<b>P Difference</b>						

**Appendix B. Sample Data Extraction Form (continued)**

<b>Net Difference</b>				
<b>P Net difference</b>				
<b>(RR/OR/HR)</b>				
<b>P (RR/OR/HR)</b>				
<b>Comments:</b>				

**FOR ANALYSES OF PREDICTORS OF OUTCOMES:**

**IF GROUPS DIVIDED BY PREDICTORS (eg, Low GFR v High GFR) INCLUDE *DETAILED RESULTS* BELOW:**

<b>Univariate:</b>	
<b>Multivariate:</b>	

**IF GROUPS DIVIDED BY OUTCOMES (eg, Dead v Alive) INCLUDE *LIST OF SIGNIFICANT ASSOCIATIONS ONLY* BELOW:**

<b>Univariate:</b>	
<b>Multivariate:</b>	

<b>Adverse Events</b>
<b>Comments:</b>

<b>Quality: (A/B/C)</b>	<b>Comments:</b>
<b>Applicability: (Low/Medium/High)</b>	<b>Comments:</b>

**Other comments:**

## Excluded Studies

Acher CW, Belzer FO, Grist TM, Turnipseed WD, Hoch JR, Archibald JE. Late renal function in patients undergoing renal revascularization for control of hypertension and/or renal preservation. *Cardiovasc Surg* 4(5):602-6. 1996  
**Pre-1993 (Surgery study)**

Adams MB, Harris SS, Kauffman HM, Towne JB. Effect of primary renal disease in patients with renovascular insufficiency. *J Vasc Surg* 1(3):482-6. 1984  
**N<100 (Surgery study)**

Ahmadi R, Schillinger M, Sabeti S, et al. Renal artery PTA and stent implantation: immediate and late clinical and morphological outcome. *Wien Klin Wochenschr* 114(1-2):21-7. 2002  
**Retrospective (PTRA study)**

Alhadad A, Mattiasson I, Ivancev K, Gottsater A, Lindblad B. Sustained beneficial effects on blood pressure during long time retrospective follow-up after endovascular treatment of renal artery occlusion. *J Human Hypertens* 18(10):739-44. 2004  
**Retrospective (PTRA study)**

Allie DE, Lirtzman MD, Wyatt CH, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. *J Invasive Cardiol* 15( 6): 334- 42. 2003.  
**Prospective treatment vs retrospective control (Question 3)**

Arlart IP, von Dewitz H, Bargon G. Transvenous digital subtraction angiography (DSA) for diagnostic control following percutaneous transluminal angioplasty (PTA) in patients with renovascular surgery. *Ann Surg* 201(2):219-2. 1985  
**N<100 (Surgery study)**

hypertension. *Eur J Radiol* 5(2):115-9. 1985  
**N<30 (PTRA study)**

Arlart IP. Digital subtraction angiography (DSA) in renal and renovascular hypertension: diagnostic value and application in follow-up studies after PTA. *Uremia Invest* 9(2):217-29. 1985  
**Pre-1993 (Surgery study)**

Askari A, Novick AC, Stewart BH, Straffon RA. Surgical treatment of renovascular disease in the solitary kidney: results in 43 cases. *J Urol* 127(1):20-2. 1982  
**N<100 (Surgery study)**

Baert AL, Wilms G, Amery A, Vermylen J, Suy R. Percutaneous transluminal renal angioplasty: initial results and long-term follow-up in 202 patients. *Cardiovasc Intervent Radiol* 13(1):22-8. 1990  
**Pre-1993 (Surgery study)**

Bakker J, Goffette PP, Henry M, et al. The Erasme study: a multicenter study on the safety and technical results of the Palmaz stent used for the treatment of atherosclerotic ostial renal artery stenosis. *Cardiovasc Intervent Radiol* 22(6):468-74. 1999

### Post-failed PTRA

Barbalias GA, Liatsikos EN, Siablis D, et al. Virtual endoscopy in renal artery stenosis: an innovative approach for diagnosis and follow-up. *J Endourol* 18(6):540-3. 2004  
**N<30 (PTRA study)**

Bardram L, Helgstrand U, Bentzen MH, Buchardt Hansen HJ, Engell HC. Late results after surgical treatment of renovascular hypertension. A follow-up study of 122 patients 2-18 years after

## Appendix C. Excluded Studies (continued)

Baumgartner I, Triller J, Mahler F. Patency of percutaneous transluminal renal angioplasty: a prospective sonographic study. *Kidney Int* 51(3):798-803. 1997

### **Prior publication of accepted study**

Baus S, Radermacher J, Galanski M, Chavan A. Kissing balloon technique for angioplasty of renal artery bifurcation stenoses. *J Vasc Interv Radiol* 14(11):1455-9. 2003

### **Retrospective (PTRA study)**

Bax L, Mali WP, van de Ven PJ, Beek FJ, Vos JA, Beutler JJ. Repeated intervention for in-stent restenosis of the renal arteries. *J Vasc Interv Radiol* 13(12):1219-24. 2002

### **Retrospective (PTRA study)**

Bedoya L, Ziegelbaum M, Vidt DG, Badhwar K, Novick AC, Gifford RW. Baseline renal function and surgical revascularization in atherosclerotic renal arterial disease in the elderly. *Cleve Clin J Med* 56(4):415-21. 1989

### **Pre-1993 (Surgery study)**

Beebe HG, MacFarlane SD. Antegrade aortorenal bypass graft: a new alternative. *Am J Surg* 155(5):647-50. 1988

### **N<100 (Surgery study)**

Bell GM, Reid J, Buist TA. Percutaneous transluminal angioplasty improves blood pressure and renal function in renovascular hypertension. *Qjm* 63(241):393-403. 1987

### **Retrospective (PTRA study)**

Bergrem H, Jervell J, Solheim DM, Flatmark A. Prognostic value of renal vein renin determination in suspected renovascular hypertension. *Acta Med Scand Suppl* 211(5):387-91. 1982

### **N<100 (Surgery study)**

Beutler JJ, Van Ampting JM, van de Ven PJ, et al. Long-term effects of arterial stenting on kidney function for patients with ostial atherosclerotic renal artery stenosis and renal insufficiency. *J Am Soc Nephrol* 12(7):1475-81. 2001

### **>20% had previous plasty**

Bhandari S, Wilkinson A, Nicholson A, Farr MJ, Sellars L. Atherosclerotic renovascular disease in the elderly: angioplasty with stenting versus reconstructive surgery. *Geriatr Nephrol Urol* 7(2):87-94. 1997

### **Retrospective (PTRA) / N<100 (Surgery)**

Binkert CA, Debatin JF, Schneider E, et al. Can MR measurement of renal artery flow and renal volume predict the outcome of percutaneous transluminal renal angioplasty?. *Cardiovasc Intervent Radiol* 24(4):233-9. 2001

### **N<30 (PTRA study)**

Blaufox MD, Fine EJ, Heller S, et al. Prospective study of simultaneous orthoiodohippurate and diethylenetriaminepentaacetic acid captopril renography. The Einstein/Cornell Collaborative Hypertension Group. *J Nucl Medicine* 39(3):522-8. 1998

### **No intervention**

Blaufox MD. Cost-effectiveness of nuclear medicine procedures in renovascular hypertension. *Semin Nucl Med* 19(2):116-21. 1989

### **Review**

Bloch MJ, Trost DA, Whitmer J, Pickering TG, Sos TA, August P. Ostial renal artery stent placement in patients 75 years of age or older. *Am J Hypertens* 14(10):983-8. 2001

### **N<30 (PTRA study)**

## Appendix C. Excluded Studies (continued)

Bloch MJ, Trost DW, Pickering TG, Sos TA, August P. Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. *Am J Hypertens* 12(1 Pt 1):1-7. 1999

### **Retrospective (PTRA study)**

Boisclair C, Therasse E, Oliva VL, et al. Treatment of renal angioplasty failure by percutaneous renal artery stenting with Palmaz stents: midterm technical and clinical results. *AJR Am J Roentgenol* 168(1):245-51. 1997

### **Post-failed PTRA**

Bonelli FS, McKusick MA, Textor SC, et al. Renal artery angioplasty: technical results and clinical outcome in 320 patients. *Mayo Clin Proc* 70(11):1041-52. 1995

### **Retrospective (PTRA study)**

Bonner G, Lederle RM, Scholze J, Stumpe KO. Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy. *Arzneimittel-Forschung* 43(8):852-5. 1993

### **Exclusion population**

Bush RL, Martin LG, Lin PH, et al. Endovascular revascularization of renal artery stenosis in the solitary functioning kidney. *Ann Vasc Surg* 15(1):60-6. 2001  
**N<30 (PTRA study)**

Bush RL, Najibi S, MacDonald MJ, et al. Endovascular revascularization of renal artery stenosis: technical and clinical results. *J Vasc Surg* 33(5):1041-9. 2001

### **Retrospective (PTRA study)**

Cambria RP, Brewster DC, L'Italien GJ, et al. The durability of different reconstructive techniques for atherosclerotic renal artery disease. *J Vasc Surg* 20(1):76-85. 1994  
**Pre-1993 (Surgery study)**

Cambria RP, Brewster DC, L'Italien GJ, et al. Renal artery reconstruction for the preservation of renal function. *J Vasc Surg* 24(3):371-80. 1996

### **Pre-1993 (Surgery study)**

Cambria RP, Kaufman JL, Brewster DC, et al. Surgical renal artery reconstruction without contrast arteriography: the role of clinical profiling and magnetic resonance angiography. *J Vasc Surg* 29(6):1012-21. 1999

### **N<100 (Surgery study)**

Campo A, Boero R, Stratta P, Quarello F. Selective stenting and the course of atherosclerotic renovascular nephropathy. *J Nephrol* 15(5):525-9. 2002

### **Retrospective (PTRA study)**

Canzanello VJ, Millan VG, Spiegel JE, Ponce PS, Kopelman RI, Madias NE. Percutaneous transluminal renal angioplasty in management of atherosclerotic renovascular hypertension: results in 100 patients. *Hypertension* 13(2):163-72. 1989

### **Pre-1993 (Surgery study)**

Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. *Circulation* 98(25):2866-72. 1998

### **No outcome of interest**

Carmichael DJ, Mathias CJ, Snell ME, Peart S. Detection and investigation of renal artery stenosis. *Lancet* 1(8482):667-70. 1986

### **Retrospective (PTRA) / N<100 (Surgery)**

Chabova V, Schirger A, Stanson AW, McKusick MA, Textor SC. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. *Mayo Clin Proc* 75(5):437-44. 2000

### **Pre-1993 (Surgery study)**

## Appendix C. Excluded Studies (continued)

Chaikof EL, Smith RB, Salam AA, et al. Empirical reconstruction of the renal artery: long-term outcome. *J Vasc Surg* 24(3):406-14. 1996

**N<100 (Surgery study)**

Chatterjee SS, Pahari DK, Sharma RK, et al. Long term follow-up of percutaneous transluminal renal angioplasty with special reference to aorto-arteritis. *Indian Heart J* 47(2):120-4. 1995

**Retrospective (PTRA study)**

Chatziioannou A, Mourikis D, Agroyannis B, et al. Renal artery stenting for renal insufficiency in solitary kidney in 26 patients. *Eur J Vasc Endovascular Surg* 23(1):49-54. 2002

**Retrospective (PTRA study)**

Cianci R, Lavini R, Letizia C, et al. Low-contrast medium doses for ultrasound imaging during renal revascularization by PTA-stenting. *J Nephrol* 17(4):520-4. 2004

**Retrospective (PTRA study)**

Cicuto KP, McLean GK, Oleaga JA, Freiman DB, Grossman RA, Ring EJ. Renal artery stenosis: anatomic classification for percutaneous transluminal angioplasty. *AJR Am J Roentgenol* 137(3):599-601. 1981

**Retrospective (PTRA study)**

Cioni R, Vignali C, Petrucci P, et al. Renal artery stenting in patients with a solitary functioning kidney. *Cardiovasc Intervent Radiol* 24(6):372-7. 2001

**Retrospective (PTRA study)**

Cognet F, Garcier JM, Dransart M, et al. Percutaneous transluminal renal angioplasty in atheroma with renal failure: long-term outcomes in 99 patients. *Eur Radiol* 11(12):2524-30. 2001

**Retrospective (PTRA study)**

Colapinto RF, Stronell RD, Harries-Jones EP, et al. Percutaneous transluminal dilatation of the renal artery: follow-up studies on renovascular hypertension. *AJR Am J Roentgenol* 139(4):727-32. 1982

**Pre-1993 (Surgery study)**

Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease. *J Am Soc Nephrol* 9(2):252-6. 1998

**Pre-1993 (Surgery study)**

Connolly JO, Higgins RM, Walters HL, et al. Presentation, clinical features and outcome in different patterns of atherosclerotic renovascular disease. *Qjm* 87(7):413-21. 1994

**Retrospective (PTRA study)**

Cormier JM, Fichelle JM, Laurian C, Gigou F, Artru B, Ricco JB. Renal artery revascularization with polytetrafluoroethylene bypass graft. *Ann Vasc Surg* 4(5):471-8. 1990

**N<100 (Surgery study)**

Crinnion JN, Gough MJ. Bilateral renal artery atherosclerosis--the results of surgical treatment. *Eur J Vasc Endovascular Surg* 11(3):353-8. 1996

**>50% had aortic reconstruction**

Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. *Am Heart J* 136(5):913-8. 1998

**No outcome of interest**

Dal Canton A, Russo D, Iaccarino V, Caputo A, D'Anna F, Andreucci VE. Percutaneous angioplasty for treatment of renovascular hypertension. *Proc Eur Dial Transplant Assoc* 20:582-6. 1983

**N<30 (PTRA study)**

## Appendix C. Excluded Studies (continued)

de Fraissinette B, Garcier JM, Dieu V, et al. Percutaneous transluminal angioplasty of dysplastic stenoses of the renal artery: results on 70 adults. *Cardiovasc Intervent Radiol* 26(1):46-51. 2003

**Retrospective (PTRA study)**

Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: anatomic and renal function changes during drug therapy. *Archives Surg* 116(11):1408-15. 1981

**Pre-1993 (Surgery study)**

Dean RH, Krueger TC, Whiteneck JM, et al. Operative management of renovascular hypertension. Results after a follow-up of fifteen to twenty-three years. *J Vasc Surg* 1(1):234-42. 1984

**N<100 (Surgery study)**

Dean RH, Tribble RW, Hansen KJ, O'Neil E, Craven TE, Redding JF. Evolution of renal insufficiency in ischemic nephropathy. *Ann Surg* 213(5):446-55. 1991

**N<100 (Surgery study)**

Dean RH. Late results of aortorenal bypass. *Urol Clin North Am* 11(3):425-34. 1984

**Pre-1993 (Surgery study)**

Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. *Am J Hypertens* 6(11 Pt 1):907-13. 1993

**Retrospective (PTRA) / N<100 (Surgery)**

Desai TR, Meyerson SL, McKinsey JF, Schwartz LB, Bassiouny HS, Gewertz BL. Angioplasty does not affect subsequent operative renal artery revascularization. *Surgery* 128(4):717-25. 2000

**N<100 (Surgery study)**

Dondi M, Fanti S, De Fabritiis A, et al. Prognostic value of captopril renal scintigraphy in renovascular hypertension. *J Nucl Medicine* 33(11):2040-4. 1992

**Pre-1993 (Surgery study)**

Donohoe P, de Takats D, Bishop N, et al. A four-year audit of interventional treatment for atheromatous renal artery stenosis. *Contrib Nephrol* 119:78-82. 1996

**Retrospective (PTRA) / N<100 (Surgery)**

Dorros G, Prince C, Mathiak L. Stenting of a renal artery stenosis achieves better relief of the obstructive lesion than balloon angioplasty. *Catheter Cardiovasc Diagn* 29(3):191-8. 1993

**N<30 (PTRA study)**

Eldrup-Jorgensen J, Harvey HR, Sampson LN, Amberson SM, Bredenberg CE. Should percutaneous transluminal renal artery angioplasty be applied to ostial renal artery atherosclerosis?. *J Vasc Surg* 21(6):909-14. 1995

**Retrospective (PTRA study)**

England WL, Roberts SD, Grim CE. Surgery or angioplasty for cost-effective renal revascularization?. *Med Dec Making* 7(2):84-91. 1987

**Retrospective (PTRA) / N<100 (Surgery)**

Erbsloh-Moller B, Dumas A, Roth D, Sfakianakis GN, Bourgoignie JJ. Furosemide-131I-hippuran renography after angiotensin-converting enzyme inhibition for the diagnosis of renovascular hypertension. *Am J Med* 90(1):23-9. 1991

**N<30 (PTRA study)**

Erdoes LS, Berman SS, Hunter GC, Mills JL. Comparative analysis of percutaneous transluminal angioplasty and operation for renal revascularization. *Am J Kidney Dis* 27(4):496-503. 1996

**Retrospective (PTRA) / N<100 (Surgery)**

## Appendix C. Excluded Studies (continued)

Esper IE, Chajari M, Fonroget J, et al. Steady-state captopril renography: continuous monitoring of the captopril-induced increase in <sup>99m</sup>Tc-MAG3 mean parenchymal transit time in renovascular hypertension. *Eur J Nucl Med* 24(7):739-44. 1997

**N<30 (PTRA study)**

Fergany A, Kolettis P, Novick AC. The contemporary role of extra-anatomical surgical renal revascularization in patients with atherosclerotic renal artery disease. *J Urol* 153(6):1798-801. 1995

**Pre-1993 (Surgery study)**

Fiala LA, Jackson MR, Gillespie DL, O'Donnell SD, Lukens M, Gorman P. Primary stenting of atherosclerotic renal artery ostial stenosis. *Ann Vasc Surg* 12(2):128-33. 1998

**Retrospective (PTRA study)**

Fichelle JM, Colacchio G, Farkas JC, et al. Renal revascularization in high-risk patients: the role of iliac renal bypass. *Ann Vasc Surg* 6(5):403-7. 1992

**N<100 (Surgery study)**

Fiorani P, Faraglia V, Aissa N, et al. Late results of reconstructive surgery for renovascular hypertension. *Int Angiol* 8(2):81-91. 1989

**Pre-1993 (Surgery study)**

Flechner S, Novick AC, Vidt D, Buonocore E, Meaney T. The use of percutaneous transluminal angioplasty for renal artery stenosis in patients with generalized atherosclerosis. *J Urol* 127(6):1072-5. 1982

**Retrospective (PTRA study)**

Fletcher JP, Simmons K, Little JM. Percutaneous transluminal angioplasty: experience at Westmead Centre. *Australas Radiol* 29(2):158-62. 1985

**Retrospective (PTRA study)**

Fommei E, Mezzasalma L, Ghione S, et al. European Captopril Radionuclide Test Multicenter Study. Preliminary results. Inspective renographic analysis. The European Captopril Radionuclide Test Multicenter Study Group. *Am J Hypertens* 4(12 Pt 2):690S-697S. 1991

**Pre-1993 (Surgery study)**

Fouad FM, Gifford RW, Fighali S, et al. Predictive value of angiotensin II antagonists in renovascular hypertension. *JAMA* 249(3):368-73. 1983

**N<100 (Surgery study)**

Fowl RJ, Hollier LH, Bernatz PE, Pairolero PC, Vogt PA, Cherry KJ. Repeat revascularization versus nephrectomy in the treatment of recurrent renovascular hypertension. *Surg Gynecol Obstet* 162(1):37-42. 1986

**N<100 (Surgery study)**

Frauchiger B, Zierler R, Bergelin RO, Isaacson JA, Strandness DE. Prognostic significance of intrarenal resistance indices in patients with renal artery interventions: a preliminary duplex sonographic study. *Cardiovasc Surg* 4(3):324-30. 1996

**N<30 (PTRA study)**

Fry RE, Fry WJ. Supraceliac aortorenal bypass with saphenous vein for renovascular hypertension. *Surg Gynecol Obstet* 168(2):180-2. 1989

**Pre-1993 (Surgery study)**

Galli M, Tarantino F, Mameli S, et al. Transradial approach for renal percutaneous transluminal angioplasty and stenting: a feasibility pilot study. *J Invasive Cardiol* 14(7):386-90. 2002

**N<30 (PTRA study)**

## Appendix C. Excluded Studies (continued)

Geroulakos G, Wright JG, Tober JC, Anderson L, Smead WL. Use of the splenic and hepatic artery for renal revascularization in patients with atherosclerotic renal artery disease. *Ann Vasc Surg* 11(1):85-9. 1997  
**N<100 (Surgery study)**

Geyskes GG, de Bruyn AJ. Captopril renography and the effect of percutaneous transluminal angioplasty on blood pressure in 94 patients with renal artery stenosis. *Am J Hypertens* 4(12 Pt 2):685S-689S. 1991  
**Pre-1993 (Surgery study)**

Geyskes GG, Puylaert CB, Oei HY, Mees EJ. Follow up study of 70 patients with renal artery stenosis treated by percutaneous transluminal dilatation. *BMJ* 287(6388):333-6. 1983  
**Retrospective (PTRA study)**

Gill IS, Novick AC, Hodge EE. Extra-anatomic renal revascularization in patients with renal artery stenosis and abdominal aortic occlusion. *Urology* 42(6):630-4. 1993  
**N<100 (Surgery study)**

Giroux MF, Soulez G, Therasse E, et al. Percutaneous revascularization of the renal arteries: predictors of outcome. *J Vasc Interv Radiol* 11(6):713-20. 2000  
**Retrospective (PTRA study)**

Giulini SM, Bonardelli S, Cangiotti L, et al. Surgery for obstructive lesions of the main trunk of the renal artery. A review of the literature and personal experience of 41 operated patients. *J Cardiovasc Surg* 36(4):329-36. 1995  
**N<100 (Surgery study)**

Greminger P, Luscher TF, Zuber J, et al. Surgery, transluminal dilatation and medical therapy in the management of renovascular hypertension. *Nephron* 44 Suppl 1:36-9. 1986  
**<50% with ARAS**

Greminger P, Vetter H, Steurer J, Siegenthaler W, Vetter W. Captopril and kidney function in renovascular and essential hypertension. *Nephron* 44 Suppl 1:91-5. 1986  
**N<10 (Medical study)**

Grim CE, Luft FC, Yune HY, Klatte EC, Weinberger MH. Percutaneous transluminal dilatation in the treatment of renal vascular hypertension. *Ann Intern Med* 95(4):439-42. 1981  
**N<30 (PTRA study)**

Grim CE, Yune HY, Donohue JP, Weinberger MH, Dilley R, Klatte EC. Renal vascular hypertension. Surgery vs. dilation. *Nephron* 44 Suppl 1:96-100. 1986  
**Retrospective (PTRA) / N<100 (Surgery)**

Grim CE, Yune HY, Weinberger MH, Donohue JP. Percutaneous transluminal dilatation or surgery in the management of renal vascular hypertension?. *Clin Sci* 61 Suppl 7:485s-486s. 1981  
**N<30 (PTRA study)**

Gruenewald SM, Collins LT, Antico VF, Farlow DC, Fawdry RM. Can quantitative renography predict the outcome of treatment of atherosclerotic renal artery stenosis?. *J Nucl Medicine* 30(12):1946-54. 1989  
**Retrospective (PTRA) / N<100 (Surgery)**

Grutzmacher P, Bussmann WD, Meyer TH, et al. Non-operative revascularisation of renal artery occlusion by transluminal angioplasty. *Nephrol Dial Transplant* 3(2):130-7. 1988  
**N<30 (PTRA study)**

Guerrero M, Syed A, Khosla S. Survival following renal artery stent revascularization: four-year follow-up. *J Invasive Cardiol* 16(7):368-71. 2004  
**Retrospective (PTRA study)**

## Appendix C. Excluded Studies (continued)

Haddad M, Barral X, Boissier C, Bouilloc X, Beraud AM. Extracorporeal repair of renal artery branch lesions. *Eur J Vasc Surg* 3(5):435-41. 1989

**N<100 (Surgery study)**

Hagino RT, Valentine RJ, Clagett GP. Supraceliac aortorenal bypass. *J Vasc Surg* 26(3):482-9. 1997

**N<100 (Surgery study)**

Hagspiel KD, Stone JR, Leung DA. Renal angioplasty and stent placement with distal protection: preliminary experience with the FilterWire EX. *J Vasc Interv Radiol* 16(1):125-31. 2005

**Retrospective (PTRA study)**

Halimi JM, Ribstein J, Du CG, Ennouchi JM, Mimran A. Albuminuria predicts renal functional outcome after intervention in atheromatous renovascular disease. *J Hypertens* 13(11):1335-42. 1995

**N<30 (PTRA study)**

Hallett JW, Fowl R, O'Brien PC, et al. Renovascular operations in patients with chronic renal insufficiency: do the benefits justify the risks?. *J Vasc Surg* 5(4):622-7. 1987

**N<100 (Surgery study)**

Hallett JW, Textor SC, Kos PB, et al. Advanced renovascular hypertension and renal insufficiency: trends in medical comorbidity and surgical approach from 1970 to 1993. *J Vasc Surg* 21(5):750-9. 1995

**Pre-1993 (Surgery study)**

Hansen KJ, Deitch JS, Oskin TC, Ligush J, Craven TE, Dean RH. Renal artery repair: consequence of operative failures. *Ann Surg* 227(5):678-89. 1998

**Post-failed PTRA**

Hansen KJ, Ditesheim JA, Metropol SH, et al. Management of renovascular hypertension in the elderly population. *J Vasc Surg* 10(3):266-73. 1989

**N<100 (Surgery study)**

Hansen KJ, Lundberg AH, Benjamin ME, et al. Is renal revascularization in diabetic patients worthwhile?. *J Vasc Surg* 24(3):383-92. 1996

**N<100 (Surgery study)**

Hansen KJ, O'Neil EA, Reavis SW, Craven TE, Plonk GW, Dean RH. Intraoperative duplex sonography during renal artery reconstruction. *J Vasc Surg* 14(3):364-74. 1991

**N<100 (Surgery study)**

Hansen KJ, Starr SM, Sands RE, Burkart JM, Plonk GW, Dean RH. Contemporary surgical management of renovascular disease. *J Vasc Surg* 16(3):319-30. 1992

**Pre-1993 (Surgery study)**

Hansen KJ, Thomason RB, Craven TE, et al. Surgical management of dialysis-dependent ischemic nephropathy. *J Vasc Surg* 21(2):197-209. 1995

**N<100 (Surgery study)**

Hansson BG, Bergentz SE, Dymling JF, Hedeland H, Hokfelt B. Pre- and postoperative studies in 72 hypertensive patients with renal artery stenosis, with special reference to renin activity and aldosterone. *Acta Med Scand Suppl* 210(4):249-55. 1981

**N<100 (Surgery study)**

Hanzel G, Balon H, Wong O, Soffer D, Lee DT, Safian RD. Prospective evaluation of aggressive medical therapy for atherosclerotic renal artery stenosis, with renal artery stenting reserved for previously injured heart, brain, or kidney. *Am J Cardiol* 96(9):1322-7. 2005

**N<30 (PTRA study; accepted for medical cohort)**

## Appendix C. Excluded Studies (continued)

Harward TR, Poindexter B, Huber TS, Carlton LM, Flynn TC, Seeger JM. Selection of patients for renal artery repair using captopril testing. *Am J Surg* 170(2):183-7. 1995

### **Retrospective (PTRA) / N<100 (Surgery)**

Harward TR, Smith S, Hawkins IF, Seeger JM. Follow-up evaluation after renal artery bypass surgery with use of carbon dioxide arteriography and color-flow duplex scanning. *J Vasc Surg* 18(1):23-30. 1993  
**N<100 (Surgery study)**

Hasbak P, Jensen LT, Ibsen H, East Danish Study Group on Renovascular Hypertension. Hypertension and renovascular disease: follow-up on 100 renal vein renin samplings. *J Human Hypertens* 16(4):275-80. 2002

### **N<30 (PTRA study)**

Helin KH, Lepantalo M, Edgren J, Liewendahl K, Tikkanen T, Tikkanen I. Predicting the outcome of invasive treatment of renal artery disease. *J Intern Medicine* 247(1):105-10. 2000  
**N<30 (PTRA study)**

Helin KH, Tikkanen I, von Knorring JE, et al. Screening for renovascular hypertension in a population with relatively low prevalence. *J Hypertens* 16(10):1523-9. 1998

### **N<30 (PTRA study)**

Hennequin LM, Joffre FG, Rousseau HP, et al. Renal artery stent placement: long-term results with the Wallstent endoprosthesis. *Radiology*. 1994

### **N<30 (PTRA study)**

Henry M, Amor M, Henry I, et al. Stent placement in the renal artery: three-year experience with the Palmaz stent. *J Vasc Interv Radiol* 7(3):343-50. 1996

### **Retrospective (PTRA study)**

Henry M, Amor M, Henry I, et al. Stents in the treatment of renal artery stenosis: long-term follow-up. *J Endovascular Surg* 6(1):42-51. 1999

### **Post-failed PTRA**

Henry M, Klonaris C, Henry I, et al. Protected renal stenting with the PercuSurge GuardWire device: a pilot study. *J Endovascular Ther* 8(3):227-37. 2001

### **N<30 (PTRA study)**

Hodsman GP, Brown JJ, Cumming AM, et al. Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. *J Hypertens Suppl* 1(1):109-17. 1983  
**<6 mo (nd AE)**

Hodsman GP, Brown JJ, Cumming AM, et al. Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition. *Am J Med* 77(2A):52-60. 1984

### **<6 mo (nd AE)**

Hoffman O, Carreres T, Sapoval MR, et al. Ostial renal artery stenosis angioplasty: immediate and mid-term angiographic and clinical results. *J Vasc Interv Radiol* 9(1 Pt 1):65-73. 1998

### **Retrospective (PTRA study)**

Holden A, Hill A. Renal angioplasty and stenting with distal protection of the main renal artery in ischemic nephropathy: early experience. *J Vasc Surg* 38(5):962-8. 2003

### **Retrospective (PTRA study)**

Hudspeth DA, Hansen KJ, Reavis SW, Starr SM, Appel RG, Dean RH. Renal duplex sonography after treatment of renovascular disease. *J Vasc Surg* 18(3):381-8. 1993

### **Pre-1993 (Surgery study)**

Hupp T, Clorius JH, Allenberg JR. Renovascular hypertension: predicting surgical cure with exercise renography. *J Vasc Surg* 14(2):200-7. 1991

### **Pre-1993 (Surgery study)**

## Appendix C. Excluded Studies (continued)

Ilkay E, Gunal IA, Yavuzkir M, et al. Effect of renal artery stenting on renal function in patients with ischemic nephropathy. *Jpn Heart J* 45(4):637-45. 2004  
**N<30 (PTRA study)**

Isles C, Main J, O'Connell J, et al. Survival associated with renovascular disease in Glasgow and Newcastle: a collaborative study. *Scott Med J* 35(3):70-3. 1990  
**Pre-1993 (Surgery study)**

Ivanovic V, McKusick MA, Johnson CM, et al. Renal artery stent placement: complications at a single tertiary care center. *J Vasc Interv Radiol* 14(2 Pt 1):217-25. 2003  
**Retrospective (PTRA study)**

Jenni R, Vieli A, Luscher TF, Schneider E, Vetter W, Anliker M. Combined two-dimensional ultrasound Doppler technique. New possibilities for the screening of renovascular and parenchymatous hypertension?. *Nephron* 44 Suppl 1:2-4. 1986  
**Retrospective (PTRA study)**

Jensen G, Moonen M, Aurell M, Granerus G, Volkmann R. Reliability of ACE inhibitor-enhanced 99Tcm-DTPA gamma camera renography in the detection of renovascular hypertension. *Nucl Med Commun* 14(3): 169-75. 1993  
**N<30 (PTRA study)**

Jensen G, Zachrisson BF, Delin K, Volkmann R, Aurell M. Treatment of renovascular hypertension: one year results of renal angioplasty. *Kidney Int* 48(6):1936-45. 1995  
**Retrospective (PTRA study)**

Joffre F, Rousseau H, Bernadet P, et al. Midterm results of renal artery stenting. *Cardiovasc Intervent Radiol* 15(5):313-8. 1992  
**N<30 (PTRA study)**

Julien J, Jeunemaitre X, Raynaud A, et al. Influence of age on the outcome of percutaneous angioplasty in atheromatous renovascular disease. *J Hypertens Suppl* 7(6):S188-9. 1989  
**Retrospective (PTRA study)**

Kadir S, Russell RP, Kaufman SL, et al. Renal artery angioplasty. Technical considerations and results. *Rofo Fortschr Geb Rontgenstr Nuklearmed* 141(4):378-83. 1984  
**N<30 (PTRA study)**

Kaplan-Pavlovic S, Nadja C. Captopril renography and duplex Doppler sonography in the diagnosis of renovascular hypertension. *Nephrol Dial Transplant* 13(2):313-7. 1998  
**N<30 (PTRA study)**

Karagiannis A, Douma S, Voyiatzis K, et al. Percutaneous transluminal renal angioplasty in patients with renovascular hypertension: long-term results. *Hypertens Res* 18(1):27-31. 1995  
**Pre-1993 (Surgery study)**

Kaylor WM, Novick AC, Ziegelbaum M, Vidt DG. Reversal of end stage renal failure with surgical revascularization in patients with atherosclerotic renal artery occlusion. *J Urol* 141(3):486-8. 1989  
**N<100 (Surgery study)**

Keith TA. Renovascular hypertension in black patients. *Hypertension* 4(3):438-43. 1982  
**Pre-1993 (Surgery study)**

Kent KC, Salvatierra O, Reilly LM, Ehrenfeld WK, Goldstone J, Stoney RJ. Evolving strategies for the repair of complex renovascular lesions. *Ann Surg* 206(3):272-8. 1987  
**N<100 (Surgery study)**

## Appendix C. Excluded Studies (continued)

Khilnani NM, Trost D, Jagust MB, Sos TA. Multiple-side-hole catheter technique for selective over-the-wire completion angiography following renal angioplasty. *J Vasc Interv Radiol* 5(2):387-9. 1994

**Retrospective (PTRA study)**

Khosla S, White CJ, Collins TJ, Jenkins JS, Shaw D, Ramee SR. Effects of renal artery stent implantation in patients with renovascular hypertension presenting with unstable angina or congestive heart failure. *Am J Cardiol* 80(3):363-6. 1997

**N<30 (PTRA study)**

Kim PK, Spriggs DW, Rutecki GW, Reaven RE, Blend D, Whittier FC. Transluminal angioplasty in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary functioning kidney. *AJR Am J Roentgenol* 153(6):1305-8. 1989

**Retrospective (PTRA study)**

Kjellbo H, Lund N, Bergentz SE, Hood B. Renal artery stenosis and hypertension. II. Mortality in operated patients compared with the mortality in individually matched medically treated patients with cryptogenetic hypertension. *Scand J Urol Nephrol* 4(1):43-7. 1970

**Pre-1993 (Surgery study)**

Klinge J, Mali WP, Puijlaert CB, Geyskes GG, Becking WB, Feldberg MA. Percutaneous transluminal renal angioplasty: initial and long-term results. *Radiology* 171(2):501-6. 1989

**Retrospective (PTRA study)**

Klow NE, Paulsen D, Vatne K, Rokstad B, Lien B, Fauchald P. Percutaneous transluminal renal artery angioplasty using the coaxial technique. Ten years of experience from 591 procedures in 419 patients. *Acta Radiol* 39(6):594-603. 1998

**Retrospective (PTRA study)**

Korsakas S, Mohaupt MG, Dinkel HP, et al. Delay of dialysis in end-stage renal failure: prospective study on percutaneous renal artery interventions. *Kidney Int* 65(1):251-8. 2004

**N<30 (PTRA study)**

Koyanagi T, Nonomura K, Takeuchi I, Watarai Y, Seki T, Kakizaki H. Surgery for renovascular diseases: a single-center experience in revascularizing renal artery stenosis and aneurysm. *Urol Int* 68(1):24-31. 2002

**N<100 (Surgery study)**

Kremer Hovinga TK, de Jong PE, de Zeeuw D, Donker AJ, Schuur KH, van der Hem GK. Restenosis prevalence and long-term effects on renal function after percutaneous transluminal renal angioplasty. *Nephron* 44 Suppl 1:64-7. 1986

**Retrospective (PTRA study)**

Krishnamurthi V, Novick AC, Myles JL. Atheroembolic renal disease: effect on morbidity and survival after revascularization for atherosclerotic renal artery stenosis. *J Urol* 161(4):1093-6. 1999

**N<100 (Surgery study)**

Kuhlmann U, Greminger P, Gruntzig A, et al. Long-term experience in percutaneous transluminal dilatation of renal artery stenosis. *Am J Med* 79(6):692-8. 1985

**Pre-1993 (Surgery study)**

Kuhlmann U, Vetter W, Furrer J, Lutolf U, Siegenthaler W, Gruntzig A. Renovascular hypertension: treatment by percutaneous transluminal dilatation. *Ann Intern Med* 92(1):1-6. 1980

**Retrospective (PTRA study)**

Kuhn FP, Kutkuhn B, Torsello G, Modder U. Renal artery stenosis: preliminary results of treatment with the Strecker stent. *Radiology* 180(2):367-72. 1991

**Retrospective (PTRA study)**

## Appendix C. Excluded Studies (continued)

Kumagai H, Suzuki H, Matsukawa S, Ryuzaki M, Saruta T. Captopril therapy following percutaneous transluminal angioplasty for bilateral renal artery stenosis. *Arch Intern Med* 149(9):1973-6. 1989

### **N<30 (PTRA study)**

Kvist S, Mulvany MJ. Reduced medication and normalization of vascular structure, but continued hypertension in renovascular patients after revascularization. *Cardiovas Res* 52(1):136-42. 2001

### **Retrospective (PTRA) / N<100 (Surgery)**

La Batide-Alanore A, Azizi M, Froissart M, Raynaud A, Plouin PF. Split renal function outcome after renal angioplasty in patients with unilateral renal artery stenosis. *J Am Soc Nephrol* 12(6):1235-41. 2001

### **N<30 (PTRA study)**

Laasonen L, Edgren J, Forslund T, Eklund B. Renal transplant artery stenosis and percutaneous transluminal angioplasty. *Acta Radiol* 26(5):609-13. 1985

### **Exclusion population**

Lagneau P, Michel JB. Surgical management and results of renal artery revascularization. *Int Angiol* 4(3):329-33. 1985

### **Pre-1993 (Surgery study)**

Lamawansa MD, Bell R, House AK. Short-term and long-term outcome following renovascular reconstruction. *Cardiovasc Surg* 3(1):50-5. 1995

### **N<100 (Surgery study)**

Lawrie GM, Morris GC, DeBakey ME. Long-term results of treatment of the totally occluded renal artery in forty patients with renovascular hypertension. *Surgery* 88(6):753-9. 1980

### **Pre-1993 (Surgery study)**

Lawrie GM, Morris GC, Glaeser DH, DeBakey ME. Renovascular reconstruction: factors affecting long-term prognosis in 919 patients followed up to 31 years. *Am J Cardiol* 63(15):1085-92. 1989

### **Pre-1993 (Surgery study)**

Lawrie GM, Morris GC, Soussou ID, et al. Late results of reconstructive surgery for renovascular disease. *Ann Surg* 191(5):528-33. 1980

### **Pre-1993 (Surgery study)**

Leertouwer TC, Derkx FH, Pattynama PM, Deinum J, van Dijk LC, Schalekamp MA. Functional effects of renal artery stent placement on treated and contralateral kidneys. *Kidney Int* 62(2):574-9. 2002

### **Retrospective (PTRA study)**

Lewis BE, Leya FS, Johnson SA, et al. Improved hemodynamic, angiographic and functional results after renal artery stenting. *J Invasive Cardiol* 6(4):136-40. 1994

### **N<30 (PTRA study)**

Li JJ, Fang CH, Jiang H, et al. Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis. *Angiology* 55(5):479-84. 2004

### **No outcome of interest**

Losinno F, Zuccala A, Busato F, Zucchelli P. Renal artery angioplasty for renovascular hypertension and preservation of renal function: long-term angiographic and clinical follow-up. *AJR Am J Roentgenol* 162(4):853-7. 1994

### **Retrospective (PTRA study)**

Lovaria A, Nicolini A, Merzaglia D, et al. Interventional radiology in the treatment of renal artery stenosis. *Ann Urol (Paris)* 33(3):146-55. 1999

### **Retrospective (PTRA study)**

## Appendix C. Excluded Studies (continued)

Lyons D, Fowler G, Petrie JC, Webster J. The haemodynamic effects of GR 32191, a thromboxane A2 receptor antagonist, in patients with renal artery stenosis and hypertension. *Br J Clin Pharmacol* 36(3):271-3. 1993

### Single dose

Mackrell PJ, Langan EM, Sullivan TM, et al. Management of renal artery stenosis: effects of a shift from surgical to percutaneous therapy on indications and outcomes. *Ann Vasc Surg* 17(1):54-9. 2003

### Retrospective (PTRA) / N<100 (Surgery)

MacLeod M, Taylor AD, Baxter G, et al. Renal artery stenosis managed by Palmaz stent insertion: technical and clinical outcome. *J Hypertens* 13(12 Pt 2):1791-5. 1995

### N<30 (PTRA study)

Madias NE, Kwon OJ, Millan VG. Percutaneous transluminal renal angioplasty. A potentially effective treatment for preservation of renal function. *Arch Intern Med* 142(4):693-7. 1982

### N<30 (PTRA study)

Mahler F, Probst P, Weidmann P, Krneta A. Transluminal dilatation of renal artery stenoses due to atherosclerosis and fibromuscular dysplasia : early results and follow-up of twelve consecutive cases. *Ann Radiol (Paris)* 24(5):355-6. 1981

### Retrospective (PTRA study)

Marekovic Z, Mokos I, Krhen I, Goreta NR, Roncevic T. Long-term outcome after surgical kidney revascularization for fibromuscular dysplasia and atherosclerotic renal artery stenosis. *J Urol* 171(3):1043-5. 2004

### N<100 (Surgery study)

Marshall FI, Hagen S, Mahaffy RG, et al. Percutaneous transluminal angioplasty for atheromatous renal artery stenosis--blood pressure response and discriminant analysis of outcome predictors. *Qjm* 75(277):483-9. 1990

### Retrospective (PTRA study)

Martin LG, Casarella WJ, Alspaugh JP, Chuang VP. Renal artery angioplasty: increased technical success and decreased complications in the second 100 patients. *Radiology* 159(3):631-4. 1986

### Retrospective (PTRA study)

Martin LG, Casarella WJ, Gaylord GM. Azotemia caused by renal artery stenosis: treatment by percutaneous angioplasty. *AJR Am J Roentgenol* 150(4):839-44. 1988

### Retrospective (PTRA study)

Martin LG, Cork RD, Kaufman SL. Long-term results of angioplasty in 110 patients with renal artery stenosis. *J Vasc Interv Radiol* 3(4):619-26. 1992

### Pre-1993 (Surgery study)

Martinez-Amenos A, Rama H, Sarrias X, Galceran J, Alsina J, Montanya X. Percutaneous transluminal angioplasty in the treatment of renovascular hypertension. *J Human Hypertens* 5(2):97-100. 1991

### Retrospective (PTRA study)

Matalon TA, Thompson MJ, Patel SK, Brunner MC, Merkel FK, Jensik SC. Percutaneous transluminal angioplasty for transplant renal artery stenosis. *J Vasc Interv Radiol* 3(1):55-8. 1992

### Exclusion population

Mathias CJ, Wilkinson AH, Pike FA, Sever PS, Peart WS. Clonidine in unilateral renal artery stenosis and unilateral renal parenchymal disease--similar antihypertensive but different renin suppressive effects. *J Hypertens Suppl* 1(2):123-5. 1983

### Single dose

## Appendix C. Excluded Studies (continued)

May J, Sheil R, Harris J, Horvath J. Failure of patent aorto-renal grafts to cure hypertension in renin positive patients. *J Cardiovasc Surg* 28(5):535-7. 1987  
**N<100 (Surgery study)**

McCready RA, Daugherty ME, Nighbert EJ, Hyde GL, Freedman AM, Ernst CB. Renal revascularization in patients with a single functioning ischemic kidney. *J Vasc Surg* 6(2):185-90. 1987  
**N<100 (Surgery study)**

McDonald DN, Smith DC, Maloney MD. Percutaneous transluminal renal angioplasty in the patient with a solitary functioning kidney. *AJR Am J Roentgenol* 151(5):1041-3. 1988

**Retrospective (PTRA study)**

Mestres CA, Campistol JM, Ninot S, et al. Improvement of renal function in azotaemic hypertensive patients after surgical revascularization. *Br J Surg* 75(6):578-80. 1988

**N<100 (Surgery study)**

Milot A, Lambert R, Lebel M, Cusson JR, Larochelle P. Prostaglandins and renal function in hypertensive patients with unilateral renal artery stenosis and patients with essential hypertension. *J Hypertens* 14(6):765-71. 1996

**No intervention**

Miranda JF, Perez MC, Plavnik F, Francisco JJ, Burihan E. Percutaneous transluminal angioplasty in the treatment of renovascular hypertension: sequential prospective study. *Sao Paulo Med J* 116(1):1613-7. 1998

**Retrospective (PTRA study)**

Miyamori I, Yasuhara S, Matsubara T, Takasaki H, Takeda R. Comparative effects of captopril and nifedipine on split renal function in renovascular hypertension. *Am J Hypertens* 1(4 Pt 1):359-63. 1988

**Case Report**

Moncure AC, Brewster DC, Darling RC, Atnip RG, Newton WD, Abbott WM. Use of the splenic and hepatic arteries for renal revascularization. *J Vasc Surg* 3(2):196-203. 1986

**N<100 (Surgery study)**

Morellato C, Bergelin RO, Cantwell-Gab K, et al. Clinical and duplex ultrasound follow-up after balloon angioplasty for atherosclerotic renal artery stenosis. *Vasc Surg* 35(2):85-93. 2001

**Retrospective (PTRA study)**

Morganti A, Quorso P, Ferraris P, et al. Time-course of the changes in blood pressure and in plasma renin activity during the first week after dilation of renal artery stenosis. *J Hypertens Suppl* 7(6):S186-7. 1989

**N<30 (PTRA study)**

Morganti A, Quorso P, Ferraris P, et al. Initial versus long-term results of percutaneous transluminal renal angioplasty in patients with renovascular hypertension. *J Hypertens Suppl* 9(6):S238-9. 1991

**N<30 (PTRA study)**

Morin JE, Hutchinson TA, Lisbona R. Long-term prognosis of surgical treatment of renovascular hypertension: a fifteen-year experience. *J Vasc Surg* 3(3):545-9. 1986  
**N<100 (Surgery study)**

Mounier-Vehier C, Haulon S, Lions C, et al. Renal atrophy in atherosclerotic renovascular disease: gradual changes 6 months after successful angioplasty. *J Endovascular Ther* 9(6):863-72. 2002

**N<30 (PTRA study)**

Murray S, Martin M, Amoedo ML, et al. Rapid decline in renal function reflects reversibility and predicts the outcome after angioplasty in renal artery stenosis. *Am J Kidney Dis* 39(1):60-6. 2002

**Retrospective (PTRA study)**

## Appendix C. Excluded Studies (continued)

Nahman NS, Maniam P, Hernandez RA, et al. Renal artery pressure gradients in patients with angiographic evidence of atherosclerotic renal artery stenosis. *Am J Kidney Dis* 24(4):695-9. 1994

**No outcome of interest**

Neymark E, LaBerge JM, Hirose R, et al. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. *Radiology* 214(3):755-60. 2000

**No intervention**

Nolan BW, Schermerhorn ML, Powell RJ, et al. Restenosis in gold-coated renal artery stents. *J Vasc Surg* 42(1):40-6. 2005

**Retrospective (PTR A study)**

Nolan BW, Schermerhorn ML, Rowell E, et al. Outcomes of renal artery angioplasty and stenting using low-profile systems. *J Vasc Surg* 41(1):46-52. 2005

**Retrospective (PTR A study)**

Novick AC, Ziegelbaum M, Vidt DG, Gifford RW, Pohl MA, Goormastic M. Trends in surgical revascularization for renal artery disease. Ten years' experience. *JAMA* 257(4):498-501. 1987

**Pre-1993 (Surgery study)**

O'Donovan RM, Gutierrez OH, Izzo JL. Preservation of renal function by percutaneous renal angioplasty in high-risk elderly patients: short-term outcome. *Nephron* 60(2):187-92. 1992

**Retrospective (PTR A study)**

Oertle M, Do DD, Baumgartner I, Triller J, Mahler F. Discrepancy of clinical and angiographic results in the follow-up of percutaneous transluminal renal angioplasty (PTR A). *Vasa* 27(3):154-7. 1998

**Retrospective (PTR A study)**

Oskin TC, Hansen KJ, Deitch JS, Craven TE, Dean RH. Chronic renal artery occlusion: nephrectomy versus revascularization. *J Vasc Surg* 29(1):140-9. 1999

**Complete occlusion**

Parildar M, Parildar Z, Oran I, Kabaroglu C, Memis A, Bayindir O. Nitric oxide and oxidative stress in atherosclerotic renovascular hypertension: effect of endovascular treatment. *J Vasc Interv Radiol* 14(7):887-92. 2003

**N<30 (PTR A study)**

Parildar Z, Gulter C, Parildar M, Oran I, Erdener D, Memis A. Effect of endovascular treatment on nitric oxide and renal function in Takayasu's arteritis with renovascular hypertension. *Kidney Blood Press Res* 25(2):91-6. 2002

**Exclusion population**

Park JS, Park JH, Kang JY, et al. Hyperfibrinogenemia is an independent risk factor for atherosclerotic renal artery stenosis. *Am J Nephrol* 19(6):649-54. 1999

**No intervention**

Park S, Jung JH, Seo HS, et al. The prevalence and clinical predictors of atherosclerotic renal artery stenosis in patients undergoing coronary angiography. *Heart Vessels* 19(6):275-9. 2004

**No intervention**

Pattynama PM, Becker GJ, Brown J, Zemel G, Benenati JF, Katzen BT. Percutaneous angioplasty for atherosclerotic renal artery disease: effect on renal function in azotemic patients. *Cardiovasc Intervent Radiol* 17(3):143-6. 1994

## Appendix C. Excluded Studies (continued)

### Retrospective (PTRA study)

Paty PS, Darling RC, Lee D, et al. Is prosthetic renal artery reconstruction a durable procedure? An analysis of 489 bypass grafts. *J Vasc Surg* 34(1):127-32. 2001

### N<100 (Surgery study)

Paulsen D, Klow NE, Rogstad B, et al. Preservation of renal function by percutaneous transluminal angioplasty in ischaemic renal disease. *Nephrol Dial Transplant* 14(6):1454-61. 1999

### Retrospective (PTRA study)

Pedersen EB, Jensen FT, Madsen B, Eiskjaer H, Nielsen JT, Rehling M. Angiotensin-converting enzyme inhibitor renography in the diagnosis of renovascular hypertension. Studies before and after angioplasty. *Nephrol Dial Transplant* 7(12):1178-84. 1992

### Retrospective (PTRA study)

Pedersen EB, Madsen B, Danielsen H, Jespersen B. Experience with percutaneous transluminal renal angioplasty in renovascular hypertension. *Acta Med Scand Suppl* 714:23-7. 1986

### N<30 (PTRA study)

Perkovic V, Thomson KR, Becker GJ. Factors affecting outcome after percutaneous renal artery stent insertion. *J Nephrol* 15(6):649-54. 2002

### Retrospective (PTRA study)

Perkovic V, Thomson KR, Mitchell PJ, et al. Treatment of renovascular disease with percutaneous stent insertion: long-term outcomes. *Australas Radiol* 45(4):438-43. 2001

### Retrospective (PTRA study)

Peterson RA, Baldauf CG, Millward SF, Aquino J, Delbrouck N. Outpatient percutaneous transluminal renal artery angioplasty: a Canadian experience. *J Vasc Interv Radiol* 11(3):327-32. 2000

### Retrospective (PTRA study)

Pfeiffer T, Reiher L, Grabitz K, et al. Reconstruction for renal artery aneurysm: operative techniques and long-term results. *J Vasc Surg* 37(2):293-300. 2003

### N<100 (Surgery study)

Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. *Lancet* 2(8610):551-2. 1988

### N<30 (PTRA study)

Plouin PF, Darne B, Chatellier G, et al. Restenosis after a first percutaneous transluminal renal angioplasty. *Hypertension* 21(1):89-96. 1993

### Retrospective (PTRA study)

Postma CT, Dennesen PJ, de Boo T, Thien T. First dose hypotension after captopril; can it be predicted? A study of 240 patients. *J Human Hypertens* 6(3):205-9. 1992

### Single dose

Postma CT, Hoefnagels WH, Barentsz JO, de Boo T, Thien T. Occlusion of unilateral stenosed renal arteries--relation to medical treatment. *J Human Hypertens* 3(3):185-90. 1989

### Retrospective (PTRA study)

Poulias GE, Skoutas B, Doundoulakis N, et al. Surgical treatment of renovascular hypertension and respective late results. A twenty years experience. *J Cardiovasc Surg* 32(1):69-75. 1991

### N<100 (Surgery study)

## Appendix C. Excluded Studies (continued)

Ramsay LE, Waller PC. Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. *BMJ* 300(6724):569-72. 1990

### **Review**

Rappelli A, Glorioso N, Madeddu P, et al. Renal vein renin in renovascular hypertension: the experience of two Italian centers. *Nephron* 44 Suppl 1:12-6. 1986

### **Retrospective (PTRA) / N<100 (Surgery)**

Raynaud AC, Beyssen BM, Turmel-Rodrigues LE, et al. Renal artery stent placement: immediate and midterm technical and clinical results. *J Vasc Interv Radiol* 5(6):849-58. 1994

### **Retrospective (PTRA study)**

Reams GP, Bauer JH. Enalapril versus triple-drug therapy in the treatment of renovascular hypertension. *Drugs* 30 Suppl 1:59-69. 1985

### **N<10 (Medical study)**

Reams GP, Singh A, Logan KW, Holmes RA, Bauer JH. Total and split renal function in patients with renovascular hypertension: effects of angiotensin-converting enzyme inhibition. *J Clin Hypertens* 3(2):153-63. 1987

### **Retrospective (PTRA study)**

Rees CR, Palmaz JC, Becker GJ, et al. Palmaz stent in atherosclerotic stenoses involving the ostia of the renal arteries: preliminary report of a multicenter study. *Radiology* 181(2):507-14. 1991

### **N<30 (PTRA study)**

Reilly JM, Rubin BG, Thompson RW, Allen BT, Anderson CB, Sicard GA. Long-term effectiveness of extraanatomic renal artery revascularization. *Surgery* 116(4):784-90. 1994

### **N<100 (Surgery study)**

Reilly JM, Rubin BG, Thompson RW, et al. Revascularization of the solitary kidney: a challenging problem in a high risk population. *Surgery* 120(4):732-6. 1996

### **N<100 (Surgery study)**

Reisfeld D, Matas AJ, Tellis VA, et al. Late follow-up of percutaneous transluminal angioplasty for treatment of transplant renal artery stenosis. *Transplant Proc* 21(1 Pt 2):1955-6. 1989

### **Exclusion population**

Ribstein J, Mourad G, Mimran A. Contrasting acute effects of captopril and nifedipine on renal function in renovascular hypertension. *Am J Hypertens* 1(3 Pt 1):239-44. 1988

### **Single dose**

Rieder CF, Iliopoulos JI, Thomas JH, Pierce GE, Hermreck AS. Trends in reconstruction for atherosclerotic renal vascular disease. *Am J Surg* 148(6):855-9. 1984

### **N<100 (Surgery study)**

Rodriguez-Lopez JA, Werner A, Ray LI, et al. Renal artery stenosis treated with stent deployment: indications, technique, and outcome for 108 patients. *J Vasc Surg* 29(4):617-24. 1999

### **Retrospective (PTRA study)**

Rodriguez-Perez JC, Plaza C, Reyes R, et al. Treatment of renovascular hypertension with percutaneous transluminal angioplasty: experience in Spain. *J Vasc Interv Radiol* 5(1):101-9. 1994

### **Retrospective (PTRA study)**

Rossi G, Feltrin GP, Miotto D, et al. Percutaneous transluminal renal angioplasty: influence of complications on long-term blood pressure results. *J Hypertens Suppl* 3 Suppl 3:S461-3. 1985

### **Retrospective (PTRA study)**

## Appendix C. Excluded Studies (continued)

Rundback JH, Gray RJ, Rozenblit G, et al. Renal artery stent placement for the management of ischemic nephropathy. *J Vasc Interv Radiol* 9(3):413-20. 1998

### **Retrospective (PTRA study)**

Rundback JH, Jacobs JM. Percutaneous renal artery stent placement for hypertension and azotemia: pilot study. *Am J Kidney Dis* 28(2):214-9. 1996

### **N<30 (PTRA study)**

Rundback JH, Manoni T, Rozenblit GN, et al. Balloon angioplasty or stent placement in patients with azotemic renovascular disease: a retrospective comparison of clinical outcomes. *Heart Dis* 1(3):121-5. 1999

### **Retrospective (PTRA study)**

Russo D, Iaccarino V, Conte G, et al. Treatment of severe renovascular hypertension by percutaneous transluminal renal angioplasty in patients with solitary functioning kidney. Effects on blood pressure and renal function. *Nephron* 50(4):315-9. 1988

### **N<30 (PTRA study)**

Sabeti S, Schillinger M, Mlekusch W, Ahmadi R, Minar E. Reduction in renal function after renal arteriography and after renal artery angioplasty. *Eur J Vasc Endovascular Surg* 24(2):156-60. 2002

### **No outcome of interest**

Sangle SR, D'Cruz DP, Abbs IC, Khamashta MA, Hughes GR. Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. *Rheumatology* 44(3):372-7. 2005

### **Exclusion population**

Sankari BR, Geisinger M, Zelch M, Brouhard B, Cunningham R, Novick AC. Post-transplant renal artery stenosis: impact of therapy on long-term kidney function and blood pressure control. *J Urol* 155(6):1860-4. 1996

### **Exclusion population**

Scheinert D, Braunlich S, Nonnast-Daniel B, et al. Transradial approach for renal artery stenting. *Catheter Cardiovasc Interv* 54(4):442-7. 2001

### **N<30 (PTRA study)**

Schwarten DE. Transluminal angioplasty of renal artery stenosis: 70 experiences. *AJR Am J Roentgenol* 135(5):969-74. 1980

### **Pre-1993 (Surgery study)**

Schwarten DE. Percutaneous transluminal angioplasty of the renal arteries: intravenous digital subtraction angiography for follow-up. *Radiology* 150(2):369-73. 1984

### **Pre-1993 (Surgery study)**

Schweiger H, Raithel D, Seyferth W, Zeitler E. Surgical treatment of renal artery occlusive disease: long term results. *J Cardiovasc Surg* 25(2):111-4. 1984

### **N<100 (Surgery study)**

Senekowitsch C, Assadian A, Wilk MV, Assadian O, Ptakovsky H, Hagmuller GW. Renal artery surgery in the era of endovascular intervention. *Vasa* 33(4):226-30. 2004

### **Retrospective (PTRA) / N<100 (Surgery)**

Shammas NW, Kapalis MJ, Dippel EJ, et al. Clinical and angiographic predictors of restenosis following renal artery stenting. *J Invasive Cardiol*. 2004

### **Retrospective (PTRA study)**

Shannon HM, Gillespie IN, Moss JG. Salvage of the solitary kidney by insertion of a renal artery stent. *AJR Am J Roentgenol* 171(1):217-22. 1998

### **N<30 (PTRA study)**

## Appendix C. Excluded Studies (continued)

Sharafuddin MJ, Raboi CA, Abu-Yousef M, Lawton WJ, Gordon JA. Renal artery stenosis: duplex US after angioplasty and stent placement. *Radiology* 220(1):168-73. 2001

**N<30 (PTRA study)**

Sharafuddin MJ, Stolpen AH, Dixon BS, Andresen KJ, Sun S, Lawton WJ. Value of MR angiography before percutaneous transluminal renal artery angioplasty and stent placement. *J Vasc Interv Radiol* 13(9 Pt 1):901-8. 2002

**Retrospective (PTRA study)**

Shifrin EG, Witz M, Morag B. Revascularisation for a poorly functioning solitary kidney. *Eur J Vasc Surg* 5(4):421-3. 1991

**N<100 (Surgery study)**

Sivamurthy N, Surowiec SM, Culakova E, et al. Divergent outcomes after percutaneous therapy for symptomatic renal artery stenosis. *J Vasc Surg* 39(3):565-74. 2004

**Retrospective (PTRA study)**

Sos TA, Pickering TG, Sniderman K, et al. Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. *N Engl J Med* 309(5):274-9. 1983

**Retrospective (PTRA study)**

Staessen J, Bulpitt C, Fagard R, Lijnen P, Amery A. Long-term converting-enzyme inhibition as a guide to surgical curability of hypertension associated with renovascular disease. *Am J Cardiol* 51(8):1317-22. 1983

**N<100 (Surgery study)**

Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. Long-term converting enzyme inhibition versus surgical treatment in hypertensive patients with renovascular disease. *Ne J Med* 27(4):161-4. 1984

**<6 mo (nd AE)**

Staessen J, Wilms G, Baert A, et al. Blood pressure during long-term converting-enzyme inhibition predicts the curability of renovascular hypertension by angioplasty. *Am J Hypertens* 1(2):208-14. 1988

**N<30 (PTRA study)**

Steinbach F, Novick AC, Campbell S, Dykstra D. Long-term survival after surgical revascularization for atherosclerotic renal artery disease. *J Urol* 158(1):38-41. 1997

**Pre-1993 (Surgery study)**

Sterner G, Weibull H, Hultberg B, et al. Determination of urinary N-acetyl-beta-glucosaminidase in patients with hypertension and renal artery stenosis. *J Intern Medicine* 234(3):281-5. 1993

**Retrospective (PTRA) / N<100 (Surgery)**

Strecker EP, Boos I, Schmid G, Gottmann D, Vetter S. Flexible tantalum stents for the treatment of renovascular hypertension: a 10-year experience. *Eur Radiol* 10(7):1144-51. 2000

**Retrospective (PTRA study)**

Stribrna J, Belan A, Vesela M, Vojtiskova H, Karasova M. Percutaneous transluminal angioplasty in renovascular hypertension. *Cor et Vasa* 27(2-3):184-90. 1985

**Pre-1993 (Surgery study)**

Stribrna J, Hejnal J, Firt P, Belan A, Pirk J, Kramar R. The effect of renal revascularization on decreased glomerular filtration rate in patients with renovascular hypertension. *Cor et Vasa* 24(1):64-70. 1982

**N<100 (Surgery study)**

Stuhrmann M, Jahnke T, Roefke C, Cramer BM. Renal artery stenosis: changes in intrarenal Doppler waveform following percutaneous transluminal angioplasty. *Cardiovasc Intervent Radiol* 21(5):380-5. 1998

**<6 mo (nd AE)**

## Appendix C. Excluded Studies (continued)

Symonides B, Chodakowska J, Januszewicz A, et al. Effects of the correction of renal artery stenosis on blood pressure, renal function and left ventricular morphology. *Blood Press* 8(3):141-50. 1999

**N<30 (PTRA study)**

Symonides B, Januszewicz A, Rowinski O, et al. Plasma fibrinogen as a risk factor for restenosis after percutaneous transluminal renal angioplasty in patients with atherosclerotic renal artery stenosis. *J Cardiovasc Risk* 6(4):269-72. 1999

**N<30 (PTRA study)**

Szostek M, Malek A, Kulesza A, Naumowski Z, Rowinski O. Early results of percutaneous renal artery angioplasty in patients with renovascular hypertension. *Cor et Vasa* 29(3):217-21. 1987

**N<30 (PTRA study)**

Tapper SS, Meacham PW. Multi-branch renal artery lesions: surgical options and results. *Cardiovasc Surg* 1(6):712-6. 1993

**N<100 (Surgery study)**

Taylor A, Sheppard D, Macleod MJ, et al. Renal artery stent placement in renal artery stenosis: technical and early clinical results. *Clin Radiol* 52(6):451-7. 1997

**N<30 (PTRA study)**

Taylor DC, Houston TM, Anderson C, Jameson M, Popatia S. Follow-up of renal and mesenteric artery revascularization with duplex ultrasonography. *Can J Surg* 39(1):17-20. 1996

**Retrospective (PTRA) / N<100 (Surgery)**

Teates CD, Tegtmeyer CJ, Croft BY, Ayers CR. Effects of percutaneous transluminal angioplasty on renal plasma flow. *Semin Nucl Med* 13(3):245-57. 1983

**Retrospective (PTRA study)**

Tegtmeyer CJ, Kellum CD, Ayers C. Percutaneous transluminal angioplasty of the renal artery. Results and long-term follow-up. *Radiology* 153(1):77-84. 1984

**Retrospective (PTRA study)**

Teunissen KE, Postma CT, van Jaarsveld BC, Derkx FH, Thien T. Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. *J Hypertens* 15(12 Pt 2):1791-6. 1997

**N<30 (PTRA study)**

Torsello G, Sachs M, Kniemeyer H, Grabitz K, Godehardt E, Sandmann W. Results of surgical treatment for atherosclerotic renovascular occlusive disease. *Eur J Vasc Surg* 4(5):477-82. 1990

**Pre-1993 (Surgery study)**

Torsello G, Szabo Z, Kutkuhn B, Kniemeyer H, Sandmann W. Ten years experience with reconstruction of the chronic totally occluded renal artery. *Eur J Vasc Surg* 1(5):327-33. 1987

**N<100 (Surgery study)**

Tullis MJ, Zierler RE, Glickerman DJ, Bergelin RO, Cantwell-Gab K, Strandness DE. Results of percutaneous transluminal angioplasty for atherosclerotic renal artery stenosis: a follow-up study with duplex ultrasonography. *J Vasc Surg* 25(1):46-54. 1997

**Retrospective (PTRA study)**

van Bockel JH, van den Akker PJ, Chang PC, Aarts JC, Hermans J, Terpstra JL. Extracorporeal renal artery reconstruction for renovascular hypertension. *J Vasc Surg* 13(1):101-10. 1991

**N<100 (Surgery study)**

## Appendix C. Excluded Studies (continued)

van Bockel JH, van Schilfgaarde R, Felthuis W, Heidema J, van Brummelen P, Terpstra JL. Surgical treatment of renovascular hypertension caused by arteriosclerosis. II. Influence of preoperative risk factors and postoperative blood pressure response on late patient survival. *Surgery* 101(4):468-77. 1987

### **Pre-1993 (Surgery study)**

van Bockel JH, van Schilfgaarde R, Felthuis W, Hermans J, Terpstra JL. Influence of preoperative risk factors and the surgical procedure on surgical mortality in renovascular hypertension. *Am J Surg* 155(6):770-5. 1988

### **Pre-1993 (Surgery study)**

van Bockel JH, van Schilfgaarde R, Felthuis W, Hermans J, van Brummelen P, Terpstra JL. Surgical treatment of renovascular hypertension caused by arteriosclerosis. I. Influence of preoperative factors on blood pressure control early and late after reconstructive surgery. *Surgery* 101(6):698-705. 1987

### **Pre-1993 (Surgery study)**

van Bockel JH, van Schilfgaarde R, Felthuis W, Overbosch EH, van Brummelen P, Terpstra JL. Reconstructive surgery for renovascular hypertension. II. Influence of patient selection and anatomical result on the blood pressure response after operation. *Qjm* 66(251):259-68. 1988

### **Pre-1993 (Surgery study)**

van Bockel JH, van Schilfgaarde R, Felthuis W, van Brummelen P, Terpstra JL. Reconstructive surgery for renovascular hypertension secondary to arteriosclerosis and fibrodysplasia. III. The early and late effects of surgery on hypertensive target organ damage. *Neth J Med* 32(3-4):159-71. 1988

### **Pre-1993 (Surgery study)**

van Bockel JH, van Schilfgaarde R, Overbosch EH, Felthuis W, Terpstra JL. The influence of the surgical technique upon the short term and long term anatomic results in reconstructive operation for renovascular hypertension. *Surg Gynecol Obstet* 166(5):402-8. 1988

### **Pre-1993 (Surgery study)**

van Bockel JH, van Schilfgaarde R, van Brummelen P, Terpstra JL. Long-term results of renal artery reconstruction with autogenous artery in patients with renovascular hypertension. *Eur J Vasc Surg* 3(6):515-21. 1989

### **N<100 (Surgery study)**

van Damme H, Jeusette F, Pans A, et al. The impact of renal revascularisation on renal dysfunction. *Eur J Vasc Endovascular Surg* 10(3):330-7. 1995

### **N<100 (Surgery study)**

van Damme H, Lombet P, Creemers E, Jeusette F, Albert A, Limet R. Surgery for occlusive renal artery disease: immediate and long-term results. *Acta Chir Belg* 95(1):1-10. 1995

### **N<100 (Surgery study)**

van de Ven PJ, Beutler JJ, Kaatee R, et al. Transluminal vascular stent for ostial atherosclerotic renal artery stenosis. *Lancet* 346(8976):672-4. 1995

### **N<30 (PTR A study)**

van Jaarsveld BC, Derkx FH, Krijnen P, et al. 'Hypertension resistant to two-drug treatment' is a useful criterion to select patients for angiography: the 'Dutch Renal Artery Stenosis Intervention Cooperative' (DRASTIC) study. *Contrib Nephrol* 119:54-8. 1996

### **No intervention**

## Appendix C. Excluded Studies (continued)

Vogt PA, Pairolero PC, Hollier LH, Fowl RJ, Cherry KJ, Bernatz PE. The occluded renal artery: durability of revascularization. *J Vasc Surg* 2(1):125-32. 1985

**N<100 (Surgery study)**

von Knorring J, Edgren J, Lepantalo M. Long-term results of percutaneous transluminal angioplasty in renovascular hypertension. *Acta Radiol* 37(1):36-40. 1996

**Retrospective (PTRA study)**

von Knorring J, Lepantalo M, Fyhrquist F. Long-term prognosis of surgical treatment of renovascular hypertension. *J Intern Medicine* 225(5):303-9. 1989

**N<100 (Surgery study)**

Watson PS, Hadjipetrou P, Cox SV, Piemonte TC, Eisenhauer AC. Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease. *Circulation* 102(14):1671-7. 2000

**N<30 (PTRA study)**

Weaver FA, Kuehne JP, Papanicolaou G. A recent institutional experience with renovascular hypertension. *Am Surg* 62(3):241-5. 1996

**Retrospective (PTRA) / N<100 (Surgery)**

Weibull H, Bergqvist D, Bergentz SE, Jonsson K, Hulthen L, Mannheim P. Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study. *J Vasc Surg* 18(5):841-50. 1993

**RCT of PTRA v surgery, not v medical. N<30 (PTRA) / Pre-1993 (Surgery)**

Weibull H, Bergqvist D, Jendteg S, et al. Clinical outcome and health care costs in renal revascularization--percutaneous transluminal renal angioplasty versus reconstructive surgery. *Br J Surg* 78(5):620-4. 1991

**Retrospective (PTRA) / N<100 (Surgery)**

Weibull H, Bergqvist D, Jonsson K, Carlsson S, Takolander R. Analysis of complications after percutaneous transluminal angioplasty of renal artery stenoses. *Eur J Vasc Surg* 1(2):77-84. 1987

**Retrospective (PTRA study)**

Weibull H, Bergqvist D, Jonsson K, Hulthen L, Mannheim P, Bergentz SE. Long-term results after percutaneous transluminal angioplasty of atherosclerotic renal artery stenosis--the importance of intensive follow-up. *Eur J Vasc Surg* 5(3):291-301. 1991

**Pre-1993 (Surgery study)**

Wenting GJ, Tan-Tjong HL, Derckx FH, de Bruyn JH, Man i, Schalekamp MA. Splint renal function after captopril in unilateral renal artery stenosis. *BMJ* 288(6421):886-90. 1984

**<6 mo (nd AE)**

Whelton PK, Harris AP, Russell RP, et al. Renovascular hypertension: results of medical and surgical therapy. *Johns Hopkins Med J* 149(6):213-9. 1981

**Pre-1993 (Surgery study)**

Wilms G, Staessen J, Baert AL, Michielsens P, Amery A. Percutaneous transluminal renal angioplasty and renal function. *Radiologie* 29(4):195-200. 1989

**Pre-1993 (Surgery study)**

Wilms GE, Baert AL, Amery AK, Staessen JA, Vermeylen JG. Short-term morphologic results of percutaneous transluminal renal angioplasty as determined with angiography. *Radiology* 170(3 Pt 2):1019-21. 1989

**Pre-1993 (Surgery study)**

Wilms GE, Peene PT, Baert AL, et al. Renal artery stent placement with use of the Wallstent endoprosthesis. *Radiology* 179(2):457-62. 1991

**N<30 (PTRA study)**

## Appendix C. Excluded Studies (continued)

Wong JM, Hansen KJ, Oskin TC, et al. Surgery after failed percutaneous renal artery angioplasty. *J Vasc Surg* 30(3):468-82. 1999

**N<100 (Surgery study)**

Xue F, Bettmann MA, Langdon DR, Wivell WA. Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting. *Radiology* 212(2):378-84. 1999

**Retrospective (PTRA) / N<100 (Surgery)**

Young N, Gruenewald SM, Wong KP. Technetium-99m DTPA renography and angiography in renal artery stenosis of varying severity. *Australas Radiol* 38(1):24-9. 1994

**Retrospective (PTRA study)**

Young N, Wong KP. Use of percutaneous transluminal balloon angioplasty to treat renovascular disease. *Australas Radiol* 36(4):289-93. 1992

**Retrospective (PTRA study)**

Yutan E, Glickerman DJ, Caps MT, et al. Percutaneous transluminal revascularization for renal artery stenosis: Veterans Affairs Puget Sound Health Care System experience. *J Vasc Surg* 34(4):685-93. 2001

**Retrospective (PTRA study)**

Zech P, Finaz d, Pozet N, et al. Surgical versus medical treatment in renovascular hypertension. Retrospective study of 166 cases. *Nephron* 44 Suppl 1:105-8. 1986

**Retrospective (Medical) / N<100 (Surgery)**

Zeller T, Muller C, Frank U, et al. Stent angioplasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis. *Catheter Cardiovasc Interv* 58(4):510-5. 2003

**Retrospective (PTRA study)**

Zhang Q, Shen W, Zhang R, Zhang J, Hu J, Zhang X. Effects of renal artery stenting on renal function and blood pressure in patients with atherosclerotic renovascular disease. *Chin Med J* 116(10):1451-4. 2003

**Retrospective (PTRA study)**

Ziegelbaum M, Novick AC, Hayes J, Vidt DG, Risius B, Gifford RW. Management of renal arterial disease in the elderly patient. *Surg Gynecol Obstet* 165(2):130-4. 1987

**Retrospective (PTRA) / N<100 (Surgery)**

Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL, Strandness DE. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. *Am J Hypertens* 9(11):1055-61. 1996

**No outcome of interest**

Zimble MS, Pickering TG, Sos TA, Laragh JH. Proteinuria in renovascular hypertension and the effects of renal angioplasty. *Am J Cardiol* 59(5):406-8. 1987

**Pre-1993 (Surgery study)**

Zuccala A, Losinno F, Gaggi R, Zucchelli P. Late improvement of renal function in patients treated by percutaneous transluminal renal angioplasty. *Contrib Nephrol* 119:74-7. 1996

**Retrospective (PTRA study)**

## Appendix D. Peer Reviewers

# Peer Reviewers

We gratefully acknowledge the following individuals who reviewed the initial draft of this Report and provided us with constructive feedback. Acknowledgments are made with the explicit statement that this does not constitute endorsement of the report by the peer reviewers.

Richard Paul Cambria, MD

**Professor of Surgery**

**Chief, Division of Vascular and  
Endovascular Surgery**

Harvard Medical School  
Boston, Massachusetts

**Richard Chapell, PhD**

Outcomes Research  
Merck & Co., Inc.

**Scott Gilbert, MD**

Assistant Professor of Medicine  
Tufts University School of Medicine  
Director, Kidney and Blood Pressure Center  
Tufts-New England Medical Center  
Boston, Massachusetts

**Linda Humphrey, MD, MPH**

Scientific Resource Center  
Oregon Health and Science University  
Portland, Oregon

**Timothy Murphy, MD**

Professor, Diagnostic Imaging  
Brown University School of Medicine  
Medical Director, Vascular Disease Research  
Center  
Rhode Island Hospital  
Providence, Rhode Island

**John H. Rundback, MD**

Associate Professor of Clinical Radiology  
College of Physicians and Surgeons of Columbia  
University  
New York, New York

**Robert Safian, MD, FSCAI** Peripheral Vascular

Disease Committee  
Society for Cardiovascular Angiography and  
Intervention  
Bethesda, Maryland

**Stephen C. Textor, M.D.**

Division of Nephrology  
Department of Medicine  
Mayo Clinic  
Rochester, Minnesota

**Katherine R. Tuttle, MD**

Director of Research  
The Heart Institute of Spokane  
Spokane, Washington

**I. David Weiner, MD**

Professor of Medicine and Physiology  
Division of Nephrology, Hypertension and  
Transplantation  
University of Florida College of Medicine  
Chief, Nephrology and Hypertension Section  
Gainesville, Florida

**Appendix D. Peer Reviewers (continued)**

**Kenneth Rosenfield, MD, FSCAI**

Chair, Peripheral Vascular Disease  
Committee  
Society for Cardiovascular Angiography and  
Intervention  
Bethesda, Maryland

**Claudia Ruiz-Zacharek, MD**

Division of Nephrology  
University of Texas Medical Branch  
Center for Devices and Radiological Health  
Food and Drug Administration

**R. Eugene Zierler, MD**

Professor of Surgery  
Division of Vascular Surgery  
University of Washington  
Seattle, Washington

**Susan J. Duval, PhD**

Assistant Professor of Epidemiology  
Division of Epidemiology  
University of Minnesota

Drs. Cambria, Gilbert, Rundback, Textor and Tuttle were also members of the EPC's Technical Expert Panel

Dr. Cambria served as the EPC technical expert consultant. As such his comments were provided on an ongoing basis.



## Detailed Summary Table

**Table.** Summary of medical, angioplasty and surgical treatments

	Angioplasty (or Surgery) vs. Medical Treatment	Medical / Natural history	Angioplasty	Surgical
<b>Data Source</b>	<ul style="list-style-type: none"> <li>• 4 RCTs (1 a mix of medical treatment and delayed angioplasty)</li> </ul>	<ul style="list-style-type: none"> <li>• 4 RCTs (1 a mix of medical treatment and delayed angioplasty)</li> <li>• 6 nonrandomized comparative studies of medical treatment, 4 prospective, 2 retrospective</li> <li>• 3 prospective cohort studies with medical treatments for blood pressure control</li> <li>• 8 cohort studies (6 prospective, 1 retrospective, and 1 mixed) of natural history or nonspecified medical treatments</li> </ul>	<ul style="list-style-type: none"> <li>• 3 RCTs</li> <li>• 6 nonrandomized comparative studies, 4 prospective, 2 retrospective; 2 included surgical revascularization</li> <li>• 20 prospective cohort studies with stent placement</li> <li>• 4 prospective cohort studies that used various approaches</li> </ul>	<ul style="list-style-type: none"> <li>• 1 RCT (versus medical treatment)</li> <li>• 2 retrospective comparisons with percutaneous angioplasty</li> <li>• 2 retrospective cohorts</li> </ul>
<b>Population studied</b>	<ul style="list-style-type: none"> <li>• See other columns</li> </ul>	<ul style="list-style-type: none"> <li>• Medical treatment studies included patients with hypertension, mean blood pressure 172-180/103-106.</li> <li>• One study included patients with &gt;50% stenosis, half of whom had bilateral disease. One included a population where 25% had bilateral disease, though the definition of RAS was unclear. The third study did not describe degree of stenosis or bilateral disease.</li> <li>• In two studies the mean serum creatinine was 1.3 mg/dL.</li> <li>• Patients had mean ages approximately in the mid-50s; however, all studies included patients in their 20s or younger.</li> <li>• In all three studies either some patients did not have ARAS or this was not reported.</li> <li>• All 3 studies were from the 1980s or earlier.</li> </ul>	<ul style="list-style-type: none"> <li>• Patients with ARAS with HTN as the most frequent indication. Also included patients with CKD, CHF</li> <li>• About 1/3 of studies included patients populations with &gt;50% stenosis, about 1/4 included only &gt;70% stenosis. Other thresholds were also used.</li> <li>• Mostly populations with both uni- and bilateral disease, range of bilateral disease generally 25-50% of patients; some populations of unilateral or bilateral disease only.</li> <li>• Comparative studies mostly had about 50% with ostial disease, when reported; cohort studies mostly with about 75% or more with ostial disease.</li> <li>• Mean age generally about 65.</li> <li>• Mean blood pressure generally in the range of 160-180/90-100.</li> <li>• Mean serum creatinine generally in the range of 1.5-2.4 mg/dL, or mean GFR about 55 mL/min.</li> </ul>	<ul style="list-style-type: none"> <li>• Patients with ARAS with HTN, CKD, or both HTN and CKD</li> <li>• Populations had <math>\geq 60\%</math> to <math>\geq 80\%</math> stenosis</li> <li>• Populations had unilateral and bilateral diseases; the range of bilateral disease was 40-60%</li> <li>• Mean age was in the 60s</li> <li>• Mean blood pressure was in the approximate range of 175-200/85-105</li> <li>• Mean serum creatinine was in the approximate range of 1.5-2.5 mg/dL</li> <li>• The interventions occurred from 1980-1999</li> </ul>

## Appendix F. Detailed Summary Table (continued)

**Table.** Summary of medical, angioplasty and surgical treatments

	Angioplasty (or Surgery) vs. Medical Treatment	Medical / Natural history	Angioplasty	Surgical
<b>Population studied, continued</b>		<ul style="list-style-type: none"> <li>• In the 8 natural history studies, populations studied were patients with RAS who received no revascularization interventions and presumably were under standard care by their physician.</li> <li>• The mean serum creatinine levels ranged from 1.2 to 3.2 mg/dL at baseline, implying at least stage 2 chronic kidney disease.</li> <li>• The mean stenosis ranged from greater than 20% to greater than 75%.</li> <li>• The percentage of bilateral stenosis ranged from 17% to 100%.</li> <li>• Mean blood pressure ranged from 143-179/77-102, although several studies did not report blood pressure.</li> <li>• The mean age was around 70 years in most studies, though 1 study followed younger patients, between 34-55 years.</li> <li>• Patients were followed from the 1970s through the late 1990s; although several studies did not report time periods.</li> </ul>	<ul style="list-style-type: none"> <li>• Comparative studies almost all did not use stents and included populations from the 1980s and 1990s. 80% of cohort studies used stents and all included populations from the mid 1990s and later.</li> </ul>	
<b>Limitations</b>	<ul style="list-style-type: none"> <li>• Only 2 RCTs compared angioplasty to medical treatment. Neither used stents. Both were of short duration (1 6-month, 1 with main analyses at 12 months, but patients followed from 3-54 months).</li> <li>• Other comparative studies were nonrandomized, retrospective, and/or evaluated interventions of secondary interest</li> </ul>	<ul style="list-style-type: none"> <li>• Data on medical treatments or natural history were from cohort studies without controls.</li> <li>• Populations studied were highly heterogeneous, limiting comparability across studies.</li> <li>• 3 studies on medical treatments reported only outcomes of blood pressure control and limited data on mortality and kidney function.</li> <li>• Treatments were not specified in 8 natural history studies.</li> <li>• Limited data on cardiovascular outcomes.</li> </ul>	<ul style="list-style-type: none"> <li>• Majority of data on angioplasty from before-after intervention studies (cohorts) without controls</li> <li>• Generally short duration of followup, often only single average time estimates of outcomes, despite range of followup time within studies.</li> <li>• Very limited data on cardiovascular outcomes.</li> <li>• Analyses of baseline variables as predictors of outcomes frequently inadequate.</li> </ul>	<ul style="list-style-type: none"> <li>• Retrospective cohort studies</li> </ul>

## Appendix F. Detailed Summary Table (continued)

**Table.** Summary of medical, angioplasty and surgical treatments

	<b>Angioplasty (or Surgery) vs. Medical Treatment</b>	<b>Medical / Natural history</b>	<b>Angioplasty</b>	<b>Surgical</b>
<b>Mortality</b>	<ul style="list-style-type: none"> <li>In the 3 comparative studies with similar patients receiving each intervention, mortality was similar with angioplasty or angioplasty / surgery and with medical treatment.</li> </ul>	<ul style="list-style-type: none"> <li>3 natural history studies found that between 1/3 and 2/3 of patients died within 4-5 years.</li> <li>Among 6 studies with medical treatment (4 comparative), wide range of mortality estimates across studies, from 0-12% at 6-9 months, and 3-38% at 1 year, and 19-69% at 2-3 years.</li> </ul>	<ul style="list-style-type: none"> <li>Wide range of mortality estimates across studies, from 1-20% at 6 months, and 0.5-23% at 1 year, and 2-53% at about 2 years. Most studies, though reported only a single mortality rate at an unspecified time point.</li> <li>Cardiovascular related death was the most frequent reported cause</li> </ul>	<ul style="list-style-type: none"> <li>5 -year mortality ranged from 12-41% in studies that used surgical revascularization or both surgery and angioplasty.</li> </ul>
<b>Kidney outcomes</b>	<ul style="list-style-type: none"> <li>No difference in kidney function (change in serum creatinine or GFR, worsening kidney function, need for dialysis) after revascularization compared to medical treatment in all but one study. One prospective nonrandomized study found a significant difference between a small decrease in serum creatinine (-0.5 mg/dL) after revascularization and a modest increase (+1.0) on medical treatment.</li> </ul>	<ul style="list-style-type: none"> <li>Kidney function outcomes were reported in seven studies (1 medical treatment and 6 natural history studies). In general patients' kidney function deteriorated over time, although to different degrees in the different studies.</li> </ul>	<ul style="list-style-type: none"> <li>Among cohort studies the improved kidney function ranged from 8-51% with the majority of studies reporting statistically non significant improvements in serum creatinine</li> <li>Kidney function improvement varied among those with lower baseline kidney function</li> </ul>	<ul style="list-style-type: none"> <li>17 % of patients became dialysis-dependent during the follow up (2 studies)</li> </ul>

## Appendix F. Detailed Summary Table (continued)

**Table.** Summary of medical, angioplasty and surgical treatments

	<b>Angioplasty (or Surgery) vs. Medical Treatment</b>	<b>Medical / Natural history</b>	<b>Angioplasty</b>	<b>Surgical</b>
<b>Blood pressure outcomes</b>	<ul style="list-style-type: none"> <li>• Comparative studies heterogeneous regarding relative effect of interventions on blood pressure.</li> <li>• One RCT of angioplasty vs. medicine found a significant net improvement with angioplasty among patients with bilateral, but not unilateral, disease. The second RCT found a net decrease in both systolic and diastolic blood pressure with angioplasty, but only the change in diastolic pressure was statistically significant. This study also found that after angioplasty, patients required fewer anti-HTN drugs; which was not found in the first RCT.</li> <li>• Most other comparative studies found no difference in blood pressure outcomes, regardless of intervention; however 2 found that blood pressure decreased more in patients on medical treatment than after angioplasty, although this effect was not significant.</li> </ul>	<ul style="list-style-type: none"> <li>• All three studies of medical treatments for blood pressure control showed that, on average, the various treatment regimens examined were effective for lowering blood pressures in RAS patients to normal ranges.</li> <li>• Outcomes of blood pressure control were reported in two natural history studies. The results were not comparable due to substantial differences in the RAS populations examined.</li> </ul>	<ul style="list-style-type: none"> <li>• The cure rates for BP outcome ranged from 4-18%, and the improved rates ranged from 35-79%. The studies also noted decreased use of anti-HTN medications compared to baseline.</li> </ul>	<ul style="list-style-type: none"> <li>• 60 - 70% of patients reported improvements in HTN (2 studies)</li> </ul>
<b>CVD outcomes</b>	<ul style="list-style-type: none"> <li>• 1 RCT of angioplasty vs. medical treatment and 1 RCT of surgery vs. medical treatment both found no differences in CVD outcomes, regardless of treatment.</li> </ul>	<ul style="list-style-type: none"> <li>• CHF events 13% and strokes 13% over 3-54 months (1 study)</li> <li>• CVD stop point (including hypertension, death, and also dialysis) 67% at about 6 years (1 study)</li> <li>• One natural history study reported eight fatal cardiovascular events in 20 patients with severe stenosis (<math>\geq 75\%</math>) during 3 to 36 months followup.</li> </ul>	<ul style="list-style-type: none"> <li>• CHF events 9%, strokes 4%, and MI 4% over 3-54 months (1 study)</li> <li>• CVD stop point (including hypertension, death, and also dialysis) 68% at about 6 years (1 study)</li> <li>• CHF 20%, MI 11%, and stroke 7% at a mean of 21 months (1 study)</li> <li>• MI 5% at 15 months (1 study)</li> </ul> <p>NYHA class changed by – 1.4 at 21 months, which was a significant improvement from baseline (1 study)</p>	<ul style="list-style-type: none"> <li>• Cardiovascular events accounted for most of the late deaths (1 study)</li> <li>• Nonfatal cardiovascular events occurred in 28% of patients at an average of almost 5 years (1 study)</li> </ul>

## Appendix F. Detailed Summary Table (continued)

	Angioplasty (or Surgery) vs. Medical Treatment	Medical / Natural history	Angioplasty	Surgical
<b>Adverse Events</b>	<ul style="list-style-type: none"> <li>Comparative studies did not address the relative adverse events or complications between interventions (except that 30-day mortality was similar in one study, 3% vs. 5%).</li> </ul>	<ul style="list-style-type: none"> <li>No study reported the 30-day mortality.</li> <li>A wide variety of adverse effects were reported for the use of enalapril, timolol, hydralazine, and captopril</li> <li>None of the 8 natural history studies reported adverse events</li> </ul>	<ul style="list-style-type: none"> <li>The 30-day mortality ranged from 0-3%.</li> <li>A transient deterioration in kidney function following procedure was reported ranged from 1-24% that included contrast-induced nephropathy. Severe decline in kidney function was also noted.</li> <li>Renal artery or parenchymal injury during procedure ranged from 1-10%.</li> <li>Periprocedural acute myocardial infarction ranged from 1-7%.</li> <li>Other complications included: major hemorrhage; renal artery occlusion or spasm; false aneurysms; severe bleeding; and localized hematoma</li> </ul>	<ul style="list-style-type: none"> <li>30 -day mortality ranged from 4-9%</li> <li>Procedural complication rate was significantly higher in combined renal artery and aortic reconstruction compared with renal artery reconstruction alone (2 studies)</li> </ul>
<b>Factors that influence outcomes</b>	<ul style="list-style-type: none"> <li>The study comparing immediate to delayed or no angioplasty found that of two diagnostic tests, recent hypertension, bilateral stenosis, and severe stenosis (&gt;70%), only bilateral disease was found to be associated with better creatinine clearance at 12 months in those patients who had immediate angioplasty, in contrast to those with unilateral disease, where creatinine clearance was statistically similar in the two groups.</li> </ul>	<ul style="list-style-type: none"> <li>Among cohort studies of medical treatment, no analyses evaluated baseline variables as predictors.</li> <li>4 natural history studies analyzed various predictors of mortality and/or outcomes of kidney function. Percent stenosis and baseline kidney function were f predictors of death (or dialysis) in separate studies. Another study found that nonspiral blood flow in the renal arteries predicted kidney function deterioration. Other variables related to cardiovascular disease were also found to predict death. 1 study found that bilateral versus unilateral disease did not predict progressive kidney disease.</li> <li>1 natural history study found that patients with bilateral disease had higher CVD mortality.</li> </ul>	<ul style="list-style-type: none"> <li>Worse baseline kidney function was associated with increased mortality, poor clinical outcomes, and relatively worse blood pressure after revascularization.</li> <li>History of, or markers of, cardiovascular disease was associated with increased mortality, poor clinical outcomes, and relatively worse kidney function after revascularization.</li> </ul>	<ul style="list-style-type: none"> <li>Preprocedure hemodialysis led to poorer functional kidney recovery but initiation of dialysis prior to surgery was predictive of long-term kidney function improvement in another (2 studies)</li> <li>Preoperative CKD, DM, prior stroke, and severe aortic occlusive disease showed significant and independent associations with death or dialysis during the follow up (1 study)</li> </ul>

## Appendix F. Detailed Summary Table (continued)

	Angioplasty (or Surgery) vs. Medical Treatment	Medical / Natural history	Angioplasty	Surgical
<b>Factors with no effect</b>	<ul style="list-style-type: none"> <li>• The study comparing immediate to delayed or no angioplasty found that no variable predicted relative effectiveness of intervention strategy when diastolic blood pressure was the outcome.</li> <li>• The randomized trial of surgical versus medical treatment, found that demographic factors did not help to predict which patients would fare better with either intervention.</li> </ul>		<ul style="list-style-type: none"> <li>• Age and beta blocker or diuretic use at baseline were not significant predictors of mortality or other clinical outcomes.</li> <li>• Baseline captopril test, renogram, arterial norepinephrine, and ACE genotype were generally not associated with outcomes.</li> <li>• The association between baseline predictors and outcomes was uncertain for several factors including baseline kidney function as a predictor of followup kidney function, baseline cardiovascular disease as a predictor or blood pressure effect, percent stenosis before angioplasty, bilateral vs. unilateral RAS, and sex.</li> </ul>	
<b>Periprocedural factors</b>	<ul style="list-style-type: none"> <li>• N/A</li> </ul>	<ul style="list-style-type: none"> <li>• N/A</li> </ul>	<ul style="list-style-type: none"> <li>• Among the studies that used angioplasty with and without stent, there were no differences in blood pressure and kidney outcomes between the procedures.</li> <li>• No study reported analyses of whether other periprocedural interventions, such as different drugs or different approaches, affected either complications or long-term outcomes.</li> </ul>	<ul style="list-style-type: none"> <li>• N/A</li> </ul>
<b>Overall Summary</b>	<ul style="list-style-type: none"> <li>• The 2 applicable RCTs found no difference in kidney cardiovascular, or mortality outcomes between angioplasty without stent placement and medical treatment. The studies suggest a better reduction in blood pressure control after angioplasty, particularly in patients with bilateral disease.</li> </ul>	<ul style="list-style-type: none"> <li>• Data on medical treatments or natural history were from cohort studies without controls.</li> <li>• Populations studied were highly heterogeneous</li> <li>• 3 natural history studies found that between 1/3 and 2/3 of patients died within 4-5 years.</li> <li>• Among 6 studies with medical treatments, wide range of mortality estimates across studies.</li> </ul>	<ul style="list-style-type: none"> <li>• Data mostly from prospective cohorts without a control group that indicate BP outcomes as the significantly improved outcome especially among those with higher baseline kidney function</li> <li>• Mortality was mostly CVD-related; was predicted by lower baseline kidney function, CHF, and influenced by bilateral disease with or without baseline CKD</li> </ul>	<ul style="list-style-type: none"> <li>• Data from retrospective cohort analyses. Some data were poorly reported.</li> <li>• Major outcomes like long-term mortality, improvements in HTN, and proportion of patients who became dialysis-dependent were similar across studies.</li> </ul>

## Appendix F. Detailed Summary Table (continued)

	Angioplasty (or Surgery) vs. Medical Treatment	Medical / Natural history	Angioplasty	Surgical
<b>Overall Summary, continued</b>	<ul style="list-style-type: none"> <li>• The other comparative studies mostly agree with these conclusions, although the studies are heterogeneous in regards to blood pressure outcomes.</li> <li>• The comparative studies do not adequately address comparative adverse events or the predictive value of baseline variables to determine whether any of these factors would favor one intervention over the other.</li> <li>• Indirect comparisons between cohort studies of revascularization and of medical treatment confirm the lack of difference in mortality rates between treatments, in resultant kidney function, with the caveat that improvement was reported only in cohort studies of revascularization,</li> <li>• Across cohort studies, the difference in blood pressure outcomes with either revascularization or medical treatment was uncertain, except that improvement was reported only in cohort studies of revascularization.</li> <li>• No conclusions could be reached about differences in cardiovascular outcomes or adverse events based on the cohort studies.</li> </ul>	<ul style="list-style-type: none"> <li>• In general patients' kidney function deteriorated over time, although to different degrees in the different studies.</li> <li>• All 3 studies of medical treatments for blood pressure control showed that, on average, the various treatment regimens examined were effective for lowering blood pressures in RAS patients to normal ranges.</li> </ul>	<ul style="list-style-type: none"> <li>• There was no difference in blood pressure and kidney outcomes between procedures with and without stent. Studies did not analyze the predictive value of periprocedural interventions</li> </ul>	

ARAS, atherosclerotic renal artery stenosis; CHF, congestive heart failure; CKD, chronic kidney disease (renal insufficiency); CVD, cardiovascular disease; DM, diabetes mellitus; GFR, glomerular filtration rate; HTN, hypertension; MI, myocardial infarction; N/A, not applicable; NYHA class, New York Heart Association functional class.